citalopram has been researched along with Anxiety in 175 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the UNWIND trial, 12 weeks of escitalopram treatment was effective in reducing anxiety." | 9.51 | Longer term benefits of exercise and escitalopram in the treatment of anxiety in patients with coronary heart disease: Six month follow-up of the UNWIND randomized clinical trial. ( Blumenthal, JA; Davidson, J; Hinderliter, A; Hoffman, BM; Jiang, W; Kraus, WE; Liao, L; Mabe, S; Sherwood, A; Smith, PJ; Watkins, LL, 2022) |
| "Controlling for age, sex, and pretreatment anxiety, escitalopram increased amygdala-VLPFC connectivity compared to placebo (F = 17." | 9.41 | Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial. ( Cecil, KM; DelBello, MP; Gong, Q; Huang, X; Li, H; Lu, L; Mills, JA; Mossman, SA; Ramsey, LB; Schroeder, HK; Strawn, JR; Sweeney, JA; Varney, ST, 2021) |
| "This study reanalyzed data from a randomized placebo-controlled trial that failed to find an effect of the selective serotonin reuptake inhibitor escitalopram on neuroticism and state anxiety in a nonclinical sample." | 9.30 | A randomized placebo-controlled trial examining the effects of escitalopram on neuroticism and state anxiety in a nonclinical sample. ( Bowen, R; Kessing, LV; Knorr, U; Peters, EM; Vinberg, M, 2019) |
| "gov NCT02516332) will evaluate the efficacy of aerobic exercise and escitalopram for improving anxiety symptoms and reducing risk for adverse clinical events in anxious CHD patients." | 9.22 | Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trial. ( Ashworth, M; Babyak, MA; Blumenthal, JA; Davidson, J; Feger, BJ; Hinderliter, A; Hoffman, BM; Jiang, W; Kraus, WE; Mabe, SK; Sherwood, A; Smith, PJ; Watkins, LL, 2016) |
| " Successful treatment of depression and anxiety with escitalopram had significant beneficial effects on suicidal ideation in these patients." | 9.22 | Determinants and escitalopram treatment effects on suicidal ideation in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, H; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Yoon, JS, 2016) |
| " We investigated the effectiveness of citalopram in the treatment of childhood functional abdominal pain (FAP)." | 9.19 | Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial. ( Gholamrezaei, A; Pourmoghaddas, Z; Roohafza, H; Saneian, H, 2014) |
| "The authors sought to determine the relative efficacy and tolerability of duloxetine versus citalopram and sertraline in the treatment of poststroke depression (PSD), anxiety, and fatigue." | 9.16 | Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. ( Karaiskos, D; Paparrigopoulos, T; Spengos, K; Tzavellas, E; Vassilopoulou, S, 2012) |
| "Patients with severe depression together with comorbid anxiety symptoms responded significantly better to treatment with escitalopram 20 mg compared with paroxetine 40 mg." | 9.14 | Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. ( Boulenger, JP; Hermes, A; Huusom, AK; Weiller, E, 2010) |
| "This study examined the potential of an antidepressant drug, escitalopram, to improve depression, resilience to stress, and quality of life in family dementia caregivers in a randomized placebo-controlled double-blinded trial." | 9.14 | Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram. ( Irwin, MR; Lavretsky, H; Siddarth, P, 2010) |
| "After three and six weeks of treatment, citalopram significantly improved abdominal pain, bloating, impact of symptoms on daily life, and overall well being compared with placebo." | 9.12 | A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. ( Broekaert, D; Fischler, B; Gevers, AM; Janssens, J; Tack, J; Van Oudenhove, L, 2006) |
| "A similar decrease in weekly rate of panic attacks, in the scores of Hamilton Scale for anxiety and depression and in the Cooper Disability Scale scores, was observed in both groups after 8 weeks, but a significant variation of outcome measures from baseline was observed already after 2 weeks in the escitalopram group (P < 0." | 9.12 | New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. ( Alvano, A; Malaguarnera, M; Raffaele, R; Rampello, L; Vecchio, I, 2006) |
| "The aim of the present study was to evaluate neuroendocrine and behavioural responses to a challenge with the selective serotonin (5-HT) reuptake inhibitor citalopram (Cit) in patients with social anxiety disorder (SAD)." | 9.11 | Citalopram challenge in social anxiety disorder. ( Aluoja, A; Maron, E; Shlik, J; Tru, I; Vasar, V, 2004) |
| "Treatment of major depression disorder with Selective serotonin reuptake inhibitors (SSRIs), such as citalopram (CTM), during pregnancy effects on the neurological trajectory of the offspring and induces enduring consequences, notably emotional and cognitive impairment." | 8.12 | Prenatal exposure of citalopram elicits depression-like and anxiety-like behaviors and alteration of morphology and protein expression of medial prefrontal cortex in young adult mice. ( Butt, MU; Du, L; Jia, M; Wang, Q; Wang, Y; Wu, J; Zahra, A, 2022) |
| "These findings suggest that PTPRZ1 variants may serve as a marker of escitalopram-mediated anxiety symptom remission in MDD." | 8.02 | Anxiety symptom remission is associated with genetic variation of PTPRZ1 among patients with major depressive disorder treated with escitalopram. ( Bousman, CA; Li, JT; Lin, JY; Liu, Q; Lv, XZ; Si, TM; Su, YA; Tian, L; Yu, X, 2021) |
| " The current study investigated whether administration of citalopram to pregnant rats could prevent anxiety and depressive-like behaviour induced by gestational stress in their offspring, and restore the expression of serotonin 1A autoreceptors in GABAergic interneurons in the medial prefrontal cortex and dorsal raphe nuclei in males, and of corticotropin-releasing factor type 2 receptors in GABAergic interneurons in the dorsal raphe nuclei in females." | 7.83 | Perinatal citalopram does not prevent the effect of prenatal stress on anxiety, depressive-like behaviour and serotonergic transmission in adult rat offspring. ( Shoham, S; Weinstock, M; Zohar, I, 2016) |
| " The aim of this study was to investigate the effects of estrus cycles and citalopram on behavior, ultrasonic vocalizations, anxiety levels, and c-fos expression in rats." | 7.80 | The effects of the estrus cycle and citalopram on anxiety-like behaviors and c-fos expression in rats. ( Bolay, H; Derinöz, O; Şahin, S; Sayin, A; Yüksel, N, 2014) |
| "The present study was aimed to evaluate the effect of escitalopram on anxiety following doxorubicin (DOX)-induced cardiomyopathy, a rodent model for heart failure (HF), in mice." | 7.79 | Effect of escitalopram on cardiomyopathy-induced anxiety in mice. ( Anwar, MJ; Pillai, KK; Samad, A; Vohora, D, 2013) |
| "In this 16-week post-marketing surveillance (PMS) study, antidepressant effects and tolerability of escitalopram was examined in 2 911 patients with comorbid depression and anxiety." | 7.79 | Treatment of comorbid anxiety and depression with escitalopram: results of a post-marketing surveillance study. ( Friede, M; Laux, G; Müller, WE, 2013) |
| "We describe the case of a pregnancy healthy outcome after in utero consecutive exposure to lamotrigine and citalopram." | 7.74 | Consecutive exposure to lamotrigine and citalopram during pregnancy. ( Gentile, S; Vozzi, F, 2007) |
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 7.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| "Escitalopram, the active enantiomer of the selective serotonin reuptake inhibitor (SSRI) citalopram, has effects in animal models for the detection of antidepressant and anxiolytic effect and in patients with major depressive and anxiety disorders." | 7.73 | Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. ( Hogg, S; Jessa, M; Michan, L, 2006) |
| "Citalopram appears to be effective and well tolerated in this group of children and adolescents with depressive or anxiety disorders and a high degree of comorbidity." | 7.71 | Citalopram in children and adolescents with depression or anxiety. ( Baumgartner, JL; Crismon, ML; Emslie, GJ, 2002) |
| "We investigated the effect of the selective serotonin reuptake inhibitor (SSRI) citalopram after 6-8 weeks and 6 months of treatment on clinical and peripheral indexes for central serotonergic function: platelet [14C]serotonin uptake and [3H]paroxetine- and [3H]LSD-binding to platelets membranes in 33 patients with panic disorder." | 7.70 | The effect of citalopram treatment on platelet serotonin function in panic disorders. ( Aberg-Wistedt, A; Neuger, J; Sinner, B; Stain-Malmgren, R; Wistedt, B, 2000) |
| "The 5HT uptake inhibitor fluoxetine had no effect on motor activity or directed exploration (head-dipping) in a holeboard test or in an elevated plusmaze test of anxiety." | 7.67 | Behavioral interactions of fluoxetine and other 5-hydroxytryptamine uptake inhibitors with ethanol in tests of anxiety, locomotion and exploration. ( Durcan, MJ; Eckardt, MJ; Linnoila, M; Lister, RG, 1988) |
| "Depression in Parkinson's disease (PD) is associated with faster progression of physical symptoms, greater decline in cognitive skills, and greater decline in the ability to care for oneself." | 6.71 | Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. ( Kaufman, K; Lauritano, M; Marin, H; Mark, M; Menza, M, 2004) |
| "Escitalopram is an effective first-line option in the management of patients with major depression, including severe forms, and various anxiety disorders." | 6.44 | Escitalopram for the treatment of major depression and anxiety disorders. ( Höschl, C; Svestka, J, 2008) |
| "We observed a linear dose-response profile with respect to geotaxis, with increasing Citalopram concentrations reducing the tendency to swim near the bottom of the tank." | 5.62 | Acute Citalopram administration modulates anxiety in response to the context associated with a robotic stimulus in zebrafish. ( Karakaya, M; Macrì, S; Porfiri, M; Scaramuzzi, A, 2021) |
| "In the UNWIND trial, 12 weeks of escitalopram treatment was effective in reducing anxiety." | 5.51 | Longer term benefits of exercise and escitalopram in the treatment of anxiety in patients with coronary heart disease: Six month follow-up of the UNWIND randomized clinical trial. ( Blumenthal, JA; Davidson, J; Hinderliter, A; Hoffman, BM; Jiang, W; Kraus, WE; Liao, L; Mabe, S; Sherwood, A; Smith, PJ; Watkins, LL, 2022) |
| "Posttraumatic stress disorder (PTSD) is a trauma-induced mental disorder characterised by fear extinction dysfunction in which fear circuit monoamines are possibly associated." | 5.43 | Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory. ( Lin, CC; Liu, YP; Tung, CS, 2016) |
| "Controlling for age, sex, and pretreatment anxiety, escitalopram increased amygdala-VLPFC connectivity compared to placebo (F = 17." | 5.41 | Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial. ( Cecil, KM; DelBello, MP; Gong, Q; Huang, X; Li, H; Lu, L; Mills, JA; Mossman, SA; Ramsey, LB; Schroeder, HK; Strawn, JR; Sweeney, JA; Varney, ST, 2021) |
| "Treatment with citalopram (5 and 10 mg/kg, ip) and desipramine (10 and 20 mg/kg, ip) for 5 days significantly improved locomotor activity, anti-anxiety like behavior in all paradigms tasks (mirror chamber, plus maze, zero maze) as compared to control (72 hr sleep-deprived)." | 5.35 | Possible role of citalopram and desipramine against sleep deprivation-induced anxiety like-behavior alterations and oxidative damage in mice. ( Garg, R; Kumar, A, 2008) |
| "A large, randomized, multicenter practical trial (International Study to Predict Optimized Treatment in Depression) in patients with current nonpsychotic MDD (N = 1,008; 722 completers) had three arms: escitalopram, sertraline, and venlafaxine-extended release." | 5.30 | Heart rate variability as a biomarker of anxious depression response to antidepressant medication. ( Gotlib, IH; Kircanski, K; Williams, LM, 2019) |
| "While dosage constraints must be considered because of citalopram's adverse effect profile, this agent's overall therapeutic effects in patients with Alzheimer's disease and agitation, in addition to efficacy for agitation/aggression, included reductions in the frequency of irritability, anxiety, and delusions; among patients who had these symptoms at week 9, they included a reduction in the severity of hallucinations but an increase in the severity of sleep/nighttime behavior disorders." | 5.22 | Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. ( Devanand, DP; Drye, LT; Frangakis, C; Leonpacher, AK; Lyketsos, CG; Makino, KM; Mintzer, JE; Munro, CA; Newell, JA; Peters, ME; Pollock, BG; Porsteinsson, AP; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2016) |
| "gov NCT02516332) will evaluate the efficacy of aerobic exercise and escitalopram for improving anxiety symptoms and reducing risk for adverse clinical events in anxious CHD patients." | 5.22 | Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trial. ( Ashworth, M; Babyak, MA; Blumenthal, JA; Davidson, J; Feger, BJ; Hinderliter, A; Hoffman, BM; Jiang, W; Kraus, WE; Mabe, SK; Sherwood, A; Smith, PJ; Watkins, LL, 2016) |
| " Successful treatment of depression and anxiety with escitalopram had significant beneficial effects on suicidal ideation in these patients." | 5.22 | Determinants and escitalopram treatment effects on suicidal ideation in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, H; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Yoon, JS, 2016) |
| " We collected blood samples from a discovery cohort of 34 adult MDD patients with co-occurring anxiety and 33 matched, nondepressed controls at baseline and after 12 weeks (of citalopram plus psychotherapy treatment for the depressed cohort)." | 5.20 | Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression. ( Bassi, S; Cyranowski, JM; Ding, Y; Guilloux, JP; Sibille, E; Tseng, G; Turecki, G; Walsh, C, 2015) |
| "Participants 18-65 years of age (N=1,008) who met criteria for major depressive disorder were randomly assigned to 8 weeks of treatment with escitalopram, sertraline, or extended-release venlafaxine." | 5.20 | Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. ( Arnow, BA; Blasey, C; Etkin, A; Kulkarni, J; Luther, JF; Palmer, DM; Rekshan, W; Rush, AJ; Schatzberg, AF; Williams, LM, 2015) |
| " Escitalopram provided no advantage over placebo in either abstinence rates from cannabis or anxiety and depression scores during the withdrawal and abstinent periods." | 5.19 | Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. ( Bar-Hamburger, R; Bloch, M; Bluvstein, I; Miller, H; Rapoport, E; Schreiber, S; Weinstein, AM, 2014) |
| " We investigated the effectiveness of citalopram in the treatment of childhood functional abdominal pain (FAP)." | 5.19 | Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial. ( Gholamrezaei, A; Pourmoghaddas, Z; Roohafza, H; Saneian, H, 2014) |
| "Objective: To assess the efficacy of selective serotonin reuptake inhibitor (SSRI) escitalopram in patients with functional dyspepsia (FD)." | 5.19 | [Psychopharmacological approach with the usage of selective serotonin reuptake inhibitors in functional dyspepsia treatment]. ( Korendovych, IV; Maliarov, SO; Revenok, KM; Svintsits'kyĭ, AS, 2014) |
| " We examined change from pre- to post-treatment in two attention measures - digit span and coding - in 133 adults aged ≥60 yr with generalized anxiety disorder in a 12-wk trial of escitalopram vs." | 5.17 | Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors. ( Butters, MA; Dixon, D; Doré, PM; Hinrichs, AL; Lenze, EJ; Lotrich, FE; Nowotny, P; Pollock, BG, 2013) |
| "We aimed to examine whether anxiety sensitivity and agoraphobic fear could affect the time taken to remission after 24 weeks of open-label escitalopram treatment of patients with panic disorder (PD)." | 5.16 | Psychological characteristics of early remitters in patients with panic disorder. ( Chung, SK; Kang, EH; Kim, EJ; Kim, JH; Kim, YR; Ku, JI; Lee, JH; Lee, SH; Lee, SY; Park, HJ; Woo, JM; Yu, BH, 2012) |
| "The authors sought to determine the relative efficacy and tolerability of duloxetine versus citalopram and sertraline in the treatment of poststroke depression (PSD), anxiety, and fatigue." | 5.16 | Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. ( Karaiskos, D; Paparrigopoulos, T; Spengos, K; Tzavellas, E; Vassilopoulou, S, 2012) |
| "Patients with severe depression together with comorbid anxiety symptoms responded significantly better to treatment with escitalopram 20 mg compared with paroxetine 40 mg." | 5.14 | Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. ( Boulenger, JP; Hermes, A; Huusom, AK; Weiller, E, 2010) |
| "This study examined the potential of an antidepressant drug, escitalopram, to improve depression, resilience to stress, and quality of life in family dementia caregivers in a randomized placebo-controlled double-blinded trial." | 5.14 | Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram. ( Irwin, MR; Lavretsky, H; Siddarth, P, 2010) |
| "After three and six weeks of treatment, citalopram significantly improved abdominal pain, bloating, impact of symptoms on daily life, and overall well being compared with placebo." | 5.12 | A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. ( Broekaert, D; Fischler, B; Gevers, AM; Janssens, J; Tack, J; Van Oudenhove, L, 2006) |
| "A similar decrease in weekly rate of panic attacks, in the scores of Hamilton Scale for anxiety and depression and in the Cooper Disability Scale scores, was observed in both groups after 8 weeks, but a significant variation of outcome measures from baseline was observed already after 2 weeks in the escitalopram group (P < 0." | 5.12 | New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. ( Alvano, A; Malaguarnera, M; Raffaele, R; Rampello, L; Vecchio, I, 2006) |
| "Among treatment-seeking elderly persons with MDD, higher anxiety symptoms and lower self-esteem predict poorer response after six weeks of escitalopram treatment." | 5.12 | Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder. ( Bensasi, S; Brown, C; Butters, MA; Cyranowski, J; Dew, MA; Frank, E; Gildengers, A; Houck, PR; Karp, JF; Lenze, EJ; Lotrich, F; Martire, L; Mazumdar, S; Miller, MD; Morse, J; Mulsant, BH; Reynolds, CF; Saghafi, R; Stack, J; Weber, E; Whyte, E, 2007) |
| "The aim of the present study was to evaluate neuroendocrine and behavioural responses to a challenge with the selective serotonin (5-HT) reuptake inhibitor citalopram (Cit) in patients with social anxiety disorder (SAD)." | 5.11 | Citalopram challenge in social anxiety disorder. ( Aluoja, A; Maron, E; Shlik, J; Tru, I; Vasar, V, 2004) |
| "Results from randomized, placebo-controlled clinical trials have demonstrated that escitalopram is effective and well tolerated in the treatment of depression and anxiety disorders." | 5.11 | Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. ( Bose, A; Rush, AJ, 2005) |
| "Short-term administration of GR205171 and citalopram alleviated social anxiety." | 5.11 | Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. ( Ahs, F; Appel, L; Bani, M; Bergström, M; Flyckt, K; Fredrikson, M; Furmark, T; Grohp, M; Jacobsson, E; Långström, B; Michelgård, A; Nilsson, LG; Pich, EM; Wahlstedt, K; Zancan, S, 2005) |
| "Sertraline and citalopram should be first-line drug treatments for anxiety and depression in pregnant women in the SSRI class." | 4.95 | What are the risks associated with different Selective Serotonin Re-uptake Inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence. ( Agius, M; Ripullone, K; Womersley, K, 2017) |
| "The effect of nicotine on both anxiety and depression has been broadly studied." | 4.31 | The effect of nicotine on antidepressant and anxiolytic responses induced by citalopram and citicoline in mice. ( Khakpai, F; Zarrindast, MR, 2023) |
| "Treatment of major depression disorder with Selective serotonin reuptake inhibitors (SSRIs), such as citalopram (CTM), during pregnancy effects on the neurological trajectory of the offspring and induces enduring consequences, notably emotional and cognitive impairment." | 4.12 | Prenatal exposure of citalopram elicits depression-like and anxiety-like behaviors and alteration of morphology and protein expression of medial prefrontal cortex in young adult mice. ( Butt, MU; Du, L; Jia, M; Wang, Q; Wang, Y; Wu, J; Zahra, A, 2022) |
| "Intranasal treatment with oxytocin showed beneficial effects in post-traumatic stress disorder and autism spectrum disorders; however, it was not investigated as much in depression." | 4.02 | Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy. ( Batinić, B; Gurwitz, D; Israel-Elgali, I; Jukić, M; Oved, K; Pešić, V; Puškaš, N; Shomron, N; Stanić, D, 2021) |
| "These findings suggest that PTPRZ1 variants may serve as a marker of escitalopram-mediated anxiety symptom remission in MDD." | 4.02 | Anxiety symptom remission is associated with genetic variation of PTPRZ1 among patients with major depressive disorder treated with escitalopram. ( Bousman, CA; Li, JT; Lin, JY; Liu, Q; Lv, XZ; Si, TM; Su, YA; Tian, L; Yu, X, 2021) |
| "Citalopram (CTM), a selective serotonin reuptake inhibitor (SSRI), has been widely used to treat panic disorders, such as depression which is one of the most disabling, yet common, psychiatric disorders." | 3.91 | Exposure to prenatal antidepressant alters medial prefrontal-striatal synchronization in mice. ( Chen, Y; Jiang, J; Long, C; Yang, L; Zahra, A; Zheng, Y, 2019) |
| "Since aggression after citalopram treatment decreased in a subgroup of animals and increased in the other, future research should focus on other possible predictors to support treatment strategies in aggressive patients." | 3.88 | Searching for neural and behavioral parameters that predict anti-aggressive effects of chronic SSRI treatment in rats. ( de Boer, SF; Gerrits, D; Homberg, JR; Peeters, D; Rietdijk, J; Rijpkema, M; Verkes, RJ, 2018) |
| " The current study investigated whether administration of citalopram to pregnant rats could prevent anxiety and depressive-like behaviour induced by gestational stress in their offspring, and restore the expression of serotonin 1A autoreceptors in GABAergic interneurons in the medial prefrontal cortex and dorsal raphe nuclei in males, and of corticotropin-releasing factor type 2 receptors in GABAergic interneurons in the dorsal raphe nuclei in females." | 3.83 | Perinatal citalopram does not prevent the effect of prenatal stress on anxiety, depressive-like behaviour and serotonergic transmission in adult rat offspring. ( Shoham, S; Weinstock, M; Zohar, I, 2016) |
| "The combination of acamprosate and escitalopram suppressed EtOH intake in both nonstressed and stressed mice; hence, this combination is potentially helpful for AUD individuals with or without comorbid depression to reduce alcohol use." | 3.83 | Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice. ( Aguiar, FS; Choi, DS; Hinton, DJ; Ho, AM; Jia, YF; Karpyak, VM; Qiu, Y; Weinshilboum, RM, 2016) |
| " This study, therefore, sought to compare the therapeutic effects of 10-Hz pulsed wave NIR (810 nm) laser with red (630 nm) laser using the same delivered energy density and Citalopram in rat chronic mild stress (CMS) model of depression and anxiety." | 3.83 | Therapeutic effects of 10-HzPulsed wave lasers in rat depression model: A comparison between near-infrared and red wavelengths. ( Mohaddes, G; Rasta, SH; Sadigh-Eteghad, S; Salarirad, S; Salehpour, F, 2016) |
| "Several clinical reports have documented a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants, in particular selective serotonin reuptake inhibitors (SSRI), in the treatment of drug-resistant depression and treatment-resistant anxiety disorders." | 3.83 | The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats. ( Kaminska, K; Rogoz, Z, 2016) |
| "The objective of the current study is to determine whether the increased anxiety of prenatally stressed (PS) rats of both sexes is associated with changes in 5HT1A and CRF type 2 receptors (5HT1AR and CRFR2) in the prefrontal cortex (PFC)-dorsal raphe nuclei (DRN) axis, and how these are affected by chronic treatment with citalopram (10 mg/kg/day)." | 3.81 | Sex dependent reduction by prenatal stress of the expression of 5HT1A receptors in the prefrontal cortex and CRF type 2 receptors in the raphe nucleus in rats: reversal by citalopram. ( Dosoretz-Abittan, L; Shoham, S; Weinstock, M; Zohar, I, 2015) |
| " AP521 showed equal or more potent anxiolytic-like effects compared with diazepam, a benzodiazepine receptor agonist, or tandospirone, a partial 5-hydroxytryptamine (5-HT)1A receptor agonist, in three rat anxiety models; the Vogel-type conflict test, elevated plus maze test, and conditioned fear stress test." | 3.81 | The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats. ( Hashimoto, S; Hattori, T; Kasahara, K; Kawakubo, H; Kawasaki, K; Nagatani, T; Nakazono, O; Takao, K; Tsujita, R, 2015) |
| "Dysfunction of cognitive control functions, but not reward-related decision making, may influence the decline of symptoms and the probability of remission of late-life depression treated with escitalopram." | 3.81 | Cognitive control, reward-related decision making and outcomes of late-life depression treated with an antidepressant. ( Alexopoulos, GS; Banerjee, S; Gunning, F; Kanellopoulos, D; Manning, K; McGovern, A; Seirup, JK, 2015) |
| "Both Bifidobacteria and escitalopram reduced anxiety in the marble burying test; however, only B." | 3.80 | Bifidobacteria exert strain-specific effects on stress-related behavior and physiology in BALB/c mice. ( Cryan, JF; Dinan, TG; Kiely, B; Savignac, HM, 2014) |
| "The present study was aimed to evaluate the effect of escitalopram on anxiety following doxorubicin (DOX)-induced cardiomyopathy, a rodent model for heart failure (HF), in mice." | 3.79 | Effect of escitalopram on cardiomyopathy-induced anxiety in mice. ( Anwar, MJ; Pillai, KK; Samad, A; Vohora, D, 2013) |
| "In this 16-week post-marketing surveillance (PMS) study, antidepressant effects and tolerability of escitalopram was examined in 2 911 patients with comorbid depression and anxiety." | 3.79 | Treatment of comorbid anxiety and depression with escitalopram: results of a post-marketing surveillance study. ( Friede, M; Laux, G; Müller, WE, 2013) |
| "Information processing bias was evaluated in a sample of 25 older adults with generalized anxiety disorder (GAD) over the course of 12 weeks of escitalopram pharmacotherapy." | 3.79 | Information processing bias and pharmacotherapy outcome in older adults with generalized anxiety disorder. ( Nguyen, H; Petkus, AJ; Steiner, AR; Wetherell, JL, 2013) |
| " The case presentation illustrates the role of pregabalin in successful medical management of this chronic pain disorder, as well as the management of common psychiatric morbidities associated with this condition." | 3.74 | Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia. ( Jerome, L, 2007) |
| "We describe the case of a pregnancy healthy outcome after in utero consecutive exposure to lamotrigine and citalopram." | 3.74 | Consecutive exposure to lamotrigine and citalopram during pregnancy. ( Gentile, S; Vozzi, F, 2007) |
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 3.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| "The purpose of the present study was to elucidate the brain regions in which citalopram, a selective serotonin reuptake inhibitor (SSRI), exerts its anxiolytic effects in conditioned fear stress (CFS) in rats, an animal model of anxiety." | 3.73 | Target brain sites of the anxiolytic effect of citalopram, a selective serotonin reuptake inhibitor. ( Inoue, T; Izumi, T; Kitaichi, Y; Koyama, T; Nakagawa, S, 2006) |
| "Escitalopram, the active enantiomer of the selective serotonin reuptake inhibitor (SSRI) citalopram, has effects in animal models for the detection of antidepressant and anxiolytic effect and in patients with major depressive and anxiety disorders." | 3.73 | Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. ( Hogg, S; Jessa, M; Michan, L, 2006) |
| "Citalopram appears to be effective and well tolerated in this group of children and adolescents with depressive or anxiety disorders and a high degree of comorbidity." | 3.71 | Citalopram in children and adolescents with depression or anxiety. ( Baumgartner, JL; Crismon, ML; Emslie, GJ, 2002) |
| "We investigated the effect of the selective serotonin reuptake inhibitor (SSRI) citalopram after 6-8 weeks and 6 months of treatment on clinical and peripheral indexes for central serotonergic function: platelet [14C]serotonin uptake and [3H]paroxetine- and [3H]LSD-binding to platelets membranes in 33 patients with panic disorder." | 3.70 | The effect of citalopram treatment on platelet serotonin function in panic disorders. ( Aberg-Wistedt, A; Neuger, J; Sinner, B; Stain-Malmgren, R; Wistedt, B, 2000) |
| "This study investigated behavioural effects of very potent 5-HT reuptake inhibitors after acute treatment (cianopramine and citalopram), as well as after chronic treatment (cianopramine), in two behavioural models of anxiety: 1) the light/dark choice procedure in mice and 2) the elevated plus-maze test in rats." | 3.69 | Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. ( Griebel, G; Jenck, F; Martin, JR; Misslin, R; Moreau, JL, 1994) |
| " These experiments investigate in mice the interactions of the 5HT reuptake inhibitors fluoxetine, citalopram and fluvoxamine and the NA uptake inhibitor desipramine with ethanol in the holeboard test and the elevated plusmaze test of anxiety." | 3.67 | Interactions of 5HT reuptake inhibitors and ethanol in tests of exploration and anxiety. ( Durcan, MJ; Eckardt, MJ; Linnoila, M; Lister, RG, 1988) |
| "The 5HT uptake inhibitor fluoxetine had no effect on motor activity or directed exploration (head-dipping) in a holeboard test or in an elevated plusmaze test of anxiety." | 3.67 | Behavioral interactions of fluoxetine and other 5-hydroxytryptamine uptake inhibitors with ethanol in tests of anxiety, locomotion and exploration. ( Durcan, MJ; Eckardt, MJ; Linnoila, M; Lister, RG, 1988) |
| "Ziprasidone augmentation was equally efficacious in treating depression in patients with versus without anxious depression." | 2.82 | Ziprasidone augmentation for anxious depression. ( Baer, L; Fava, M; Ionescu, DF; Meade, KH; Papakostas, GI; Shelton, RC; Swee, MB, 2016) |
| "Depression in Parkinson's disease (PD) is associated with faster progression of physical symptoms, greater decline in cognitive skills, and greater decline in the ability to care for oneself." | 2.71 | Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. ( Kaufman, K; Lauritano, M; Marin, H; Mark, M; Menza, M, 2004) |
| "Moreover, the treatment of depression and anxiety can be associated with a reduced mortality." | 2.66 | Mood disorders and outcomes in lung cancer patients undergoing surgery: a brief summery. ( Aguglia, E; Migliore, M; Signorelli, MS; Surace, T, 2020) |
| "To assess the risk of headache associated with commonly prescribed antidepressant medications and to examine the impact of medication class, pharmacodynamics and dosage on risk of headache." | 2.58 | Meta-analysis: Second generation antidepressants and headache. ( Bloch, MH; Olten, B; Telang, S; Walton, C, 2018) |
| "Somatic anxiety, psychic anxiety and psychomotor agitation as assessed using the Hamilton Depression Rating Scale (HDRS) were analysed in all trials (n = 8262); anxiety-related adverse events were analysed in trials investigating paroxetine and citalopram (n = 5712)." | 2.55 | Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression. ( Emilsson, JF; Eriksson, E; Hieronymus, F; Lisinski, A; Näslund, J; Nilsson, S, 2017) |
| "Stroke is the major cause of adult disability." | 2.48 | Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. ( Claxton, A; Hackett, ML; Hankey, GJ; Hsieh, CF; Kutlubaev, MA; Lee, R; Mead, GE, 2012) |
| "Escitalopram is an effective first-line option in the management of patients with major depression, including severe forms, and various anxiety disorders." | 2.44 | Escitalopram for the treatment of major depression and anxiety disorders. ( Höschl, C; Svestka, J, 2008) |
| "Our results revealed that REM sleep deprivation reduced the percentage of open arm time (%OAT) and the percentage of the open arm entries (%OAE) but not closed arm entries (locomotor activity) in the EPM test, presenting an anxiogenic response ( P < 0." | 1.72 | The effects of citalopram, SB-334867 and orexin-1, alone or in various combinations, on the anxiogenic-like effects of REM sleep deprivation in male mice. ( Alibeik, H; Bananej, M; Khakpai, F; Saadati, N; Zarrindast, MR, 2022) |
| "In particularly, the methods evaluating hearing disorders are not well established in animal models, limiting the pre-clinical research on its mechanism." | 1.56 | Attenuation of auditory mismatch negativity in serotonin transporter knockout mice with anxiety-related behaviors. ( Chen, F; Chen, P; Li, C; Lyu, K; Pan, W; Tang, J; Ying, M; Zhang, H, 2020) |
| "The condition has been referred to as Morgellons disease." | 1.48 | Morgellons disease: experiences of an integrated multidisciplinary dermatology team to achieve positive outcomes. ( Bewley, A; Mohandas, P; Taylor, R, 2018) |
| "Posttraumatic stress disorder (PTSD) is a trauma-induced mental disorder characterised by fear extinction dysfunction in which fear circuit monoamines are possibly associated." | 1.43 | Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory. ( Lin, CC; Liu, YP; Tung, CS, 2016) |
| "The anxiety-reducing effect of long-term administration of serotonin reuptake inhibitors is usually seen only in subjects with anxiety disorders, and such patients are also abnormally inclined to experience a paradoxical anxiety-enhancing effect of acute serotonin reuptake inhibition." | 1.42 | Differences in Anxiety-Like Behavior within a Batch of Wistar Rats Are Associated with Differences in Serotonergic Transmission, Enhanced by Acute SRI Administration, and Abolished By Serotonin Depletion. ( Eriksson, E; Hagsäter, M; Näslund, J; Nilsson, S; Nissbrandt, H; Pettersson, R; Studer, E, 2015) |
| "Depression during pregnancy has been linked to in utero stress and is associated with long-lasting symptoms in offspring, including anxiety, helplessness, attentional deficits, and social withdrawal." | 1.42 | Prenatal stress, regardless of concurrent escitalopram treatment, alters behavior and amygdala gene expression of adolescent female rats. ( Bourke, CH; Ehrlich, DE; Hazra, R; Jairam, N; Neigh, GN; Nemeth, CL; Owens, MJ; Rainnie, DG; Rowson, S; Ryan, SJ; Sholar, CA; Stowe, ZN, 2015) |
| "Escitalopram treatment decreased anxiety-related behaviours in stressed animals, by increasing the time spent in the central part of the arena with respect to saline treated stressed animals, without affecting exploratory related behaviours." | 1.40 | Behavioural and transcriptional effects of escitalopram in the chronic escape deficit model of depression. ( Alboni, S; Benatti, C; Blom, JM; Brunello, N; Gandolfi, F; Mendlewicz, J; Tascedda, F, 2014) |
| "Fatigue is a common symptom in individuals with multiple sclerosis (MS)." | 1.39 | Reward responsiveness and fatigue in multiple sclerosis. ( Capello, E; Krueger, F; Mancardi, G; Pardini, M; Uccelli, A, 2013) |
| "Escitalopram was more effective than placebo, and as effective as the SSRIs and SNRIs, in the treatment of anxious MDD." | 1.37 | Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. ( Larsen, K; Papakostas, GI, 2011) |
| "Pre-treatment with diazepam (0." | 1.37 | Acute anxiogenic-like effects of selective serotonin reuptake inhibitors are attenuated by the benzodiazepine diazepam in BALB/c mice. ( Birkett, MA; Kessler, EJ; Meyer, JS; Ritchie, S; Rowlett, JK; Shinday, NM, 2011) |
| "Participants with either anxiety or substance use disorder showed outcomes generally intermediate between those with both and those with neither." | 1.35 | Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. ( Balasubramani, GK; Berman, SR; Davis, LL; Fava, M; Howland, RH; McGrath, PJ; Rush, AJ; Trivedi, MH; Warden, D; Wisniewski, SR, 2009) |
| "Treatment with citalopram (5 and 10 mg/kg, ip) and desipramine (10 and 20 mg/kg, ip) for 5 days significantly improved locomotor activity, anti-anxiety like behavior in all paradigms tasks (mirror chamber, plus maze, zero maze) as compared to control (72 hr sleep-deprived)." | 1.35 | Possible role of citalopram and desipramine against sleep deprivation-induced anxiety like-behavior alterations and oxidative damage in mice. ( Garg, R; Kumar, A, 2008) |
| "Citalopram prevented the increase in sucrose consumption in the PCA+CVS rats, and in 5-HT-depleted animals blocked the increase in struggling and reduced the number of defecations in the forced swim test." | 1.35 | Rat behavior after chronic variable stress and partial lesioning of 5-HT-ergic neurotransmission: effects of citalopram. ( Eller, M; Häidkind, R; Harro, J; Kõiv, K; Mällo, T; Tõnissaar, M, 2008) |
| " dosing of a novel MCHR1 antagonist, N-[3-(1-{[4-(3,4-difluorophenoxy)-phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847), in three mouse models predictive of antidepressant/anxiolytic-like activity: novelty suppressed feeding (NSF) in 129S6/SvEvTac mice and light/dark paradigm (L/D) and forced swim test (FST) in BALB/cJ mice." | 1.34 | Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocam ( Craig, DA; David, DJ; Dong, D; Gerald, CP; Hegde, LG; Hen, R; Holick, KA; Klemenhagen, KC; Marzabadi, MR; Mendez, I; Ping, XI; Santarelli, L; Saxe, MD; Swanson, CJ; Zhong, H, 2007) |
| " The dose-response curve was biphasic for citalopram with a maximum of 64% inhibition." | 1.30 | Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? ( Meier, E; Sánchez, C, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (1.71) | 18.7374 |
| 1990's | 6 (3.43) | 18.2507 |
| 2000's | 53 (30.29) | 29.6817 |
| 2010's | 88 (50.29) | 24.3611 |
| 2020's | 25 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Taler, M | 1 |
| Gil-Ad, I | 1 |
| Brener, I | 1 |
| Hornfeld, SH | 1 |
| Weizman, A | 2 |
| Zahra, A | 3 |
| Du, L | 1 |
| Jia, M | 1 |
| Butt, MU | 1 |
| Wang, Q | 1 |
| Wang, Y | 2 |
| Wu, J | 1 |
| Simonoff, E | 1 |
| Mowlem, F | 1 |
| Pearson, O | 1 |
| Anagnostou, E | 1 |
| Donnelly, C | 1 |
| Hollander, E | 1 |
| King, BH | 1 |
| McCracken, JT | 1 |
| Scahill, L | 1 |
| Sikich, L | 1 |
| Pickles, A | 1 |
| Collins, HM | 1 |
| Pinacho, R | 1 |
| Ozdemir, D | 1 |
| Bannerman, DM | 1 |
| Sharp, T | 1 |
| Blumenthal, JA | 2 |
| Smith, PJ | 2 |
| Jiang, W | 2 |
| Hinderliter, A | 2 |
| Watkins, LL | 2 |
| Hoffman, BM | 2 |
| Kraus, WE | 2 |
| Mabe, S | 1 |
| Liao, L | 1 |
| Davidson, J | 2 |
| Sherwood, A | 2 |
| Kalbouneh, HM | 1 |
| Toubasi, AA | 1 |
| Albustanji, FH | 1 |
| Obaid, YY | 1 |
| Al-Harasis, LM | 1 |
| Saadati, N | 1 |
| Bananej, M | 1 |
| Khakpai, F | 3 |
| Zarrindast, MR | 3 |
| Alibeik, H | 1 |
| Peters, EM | 1 |
| Knorr, U | 1 |
| Vinberg, M | 1 |
| Kessing, LV | 1 |
| Bowen, R | 1 |
| Pan, W | 1 |
| Lyu, K | 1 |
| Zhang, H | 1 |
| Li, C | 1 |
| Chen, P | 1 |
| Ying, M | 1 |
| Chen, F | 1 |
| Tang, J | 1 |
| Ji, OS | 1 |
| Karalis, PG | 1 |
| Daas, M | 1 |
| Condon, J | 1 |
| Nejati, S | 1 |
| Liao, XM | 1 |
| Su, YA | 2 |
| Yu, X | 2 |
| Si, TM | 2 |
| Signorelli, MS | 1 |
| Surace, T | 1 |
| Migliore, M | 1 |
| Aguglia, E | 1 |
| Aguilar-Martinez, IS | 1 |
| Reyes-Mendez, ME | 1 |
| Herrera-Zamora, JM | 1 |
| Osuna-Lopez, F | 1 |
| Virgen-Ortiz, A | 1 |
| Mendoza-Munoz, N | 1 |
| Gongora-Alfaro, JL | 1 |
| Moreno-Galindo, EG | 1 |
| Alamilla, J | 1 |
| Quah, SKL | 1 |
| McIver, L | 1 |
| Roberts, AC | 2 |
| Santangelo, AM | 1 |
| Tirmazi, SI | 1 |
| Imran, H | 1 |
| Rasheed, A | 1 |
| Mushtaq, S | 1 |
| Firoozeei, TS | 1 |
| Barekatain, M | 1 |
| Karimi, M | 1 |
| Zargaran, A | 1 |
| Akhondzadeh, S | 1 |
| Rezaeizadeh, H | 1 |
| Bregin, A | 1 |
| Kaare, M | 1 |
| Jagomäe, T | 1 |
| Karis, K | 1 |
| Singh, K | 1 |
| Laugus, K | 1 |
| Innos, J | 1 |
| Leidmaa, E | 1 |
| Heinla, I | 1 |
| Visnapuu, T | 1 |
| Oja, EM | 1 |
| Kõiv, K | 3 |
| Lilleväli, K | 1 |
| Harro, J | 4 |
| Philips, MA | 1 |
| Vasar, E | 1 |
| Karakaya, M | 1 |
| Scaramuzzi, A | 1 |
| Macrì, S | 1 |
| Porfiri, M | 1 |
| Audley, GG | 1 |
| Frankenfeld, P | 1 |
| Dlamini, S | 1 |
| Raubenheimer, P | 1 |
| Hoare, J | 1 |
| Cairncross, L | 1 |
| Van den Berg, R | 1 |
| Gule, MV | 1 |
| Calligaro, G | 1 |
| Lu, L | 1 |
| Mills, JA | 1 |
| Li, H | 1 |
| Schroeder, HK | 1 |
| Mossman, SA | 1 |
| Varney, ST | 1 |
| Cecil, KM | 1 |
| Huang, X | 1 |
| Gong, Q | 1 |
| Ramsey, LB | 1 |
| DelBello, MP | 1 |
| Sweeney, JA | 2 |
| Strawn, JR | 1 |
| Stanić, D | 1 |
| Oved, K | 1 |
| Israel-Elgali, I | 1 |
| Jukić, M | 1 |
| Batinić, B | 1 |
| Puškaš, N | 1 |
| Shomron, N | 1 |
| Gurwitz, D | 1 |
| Pešić, V | 1 |
| Burstein, O | 1 |
| Simon, N | 1 |
| Simchon-Tenenbaum, Y | 1 |
| Rehavi, M | 2 |
| Franko, M | 2 |
| Shamir, A | 1 |
| Doron, R | 2 |
| Liu, K | 1 |
| Garcia, A | 1 |
| Park, JJ | 1 |
| Toliver, AA | 1 |
| Ramos, L | 1 |
| Aizenman, CD | 1 |
| Bousman, CA | 1 |
| Liu, Q | 2 |
| Lv, XZ | 1 |
| Li, JT | 1 |
| Lin, JY | 1 |
| Tian, L | 1 |
| Mohandas, P | 1 |
| Bewley, A | 1 |
| Taylor, R | 1 |
| Näslund, J | 3 |
| Hieronymus, F | 1 |
| Emilsson, JF | 1 |
| Lisinski, A | 1 |
| Nilsson, S | 3 |
| Eriksson, E | 3 |
| Womersley, K | 1 |
| Ripullone, K | 1 |
| Agius, M | 1 |
| Varela, MJ | 1 |
| Acanda de la Rocha, AM | 1 |
| Díaz, A | 1 |
| Lopez-Gimenez, JF | 1 |
| Koek, W | 1 |
| Mitchell, NC | 1 |
| Daws, LC | 1 |
| Telang, S | 1 |
| Walton, C | 1 |
| Olten, B | 1 |
| Bloch, MH | 1 |
| Jiang, J | 2 |
| Chen, Y | 2 |
| Long, C | 2 |
| Yang, L | 2 |
| Aguilar-Valles, A | 1 |
| Haji, N | 1 |
| De Gregorio, D | 1 |
| Matta-Camacho, E | 1 |
| Eslamizade, MJ | 1 |
| Popic, J | 1 |
| Sharma, V | 1 |
| Cao, R | 1 |
| Rummel, C | 1 |
| Tanti, A | 1 |
| Wiebe, S | 1 |
| Nuñez, N | 1 |
| Comai, S | 1 |
| Nadon, R | 1 |
| Luheshi, G | 1 |
| Mechawar, N | 1 |
| Turecki, G | 2 |
| Lacaille, JC | 1 |
| Gobbi, G | 1 |
| Sonenberg, N | 1 |
| Peeters, D | 1 |
| Rietdijk, J | 1 |
| Gerrits, D | 1 |
| Rijpkema, M | 1 |
| de Boer, SF | 1 |
| Verkes, RJ | 1 |
| Homberg, JR | 1 |
| Aisenberg Romano, G | 1 |
| Fried Zaig, I | 1 |
| Halevy, A | 1 |
| Azem, F | 1 |
| Amit, A | 1 |
| Bloch, M | 2 |
| Kircanski, K | 1 |
| Williams, LM | 3 |
| Gotlib, IH | 1 |
| Prabhakar, D | 1 |
| Sablaban, I | 1 |
| Zheng, Y | 1 |
| Braund, TA | 1 |
| Palmer, DM | 2 |
| Harris, AWF | 1 |
| Hou, R | 1 |
| Ye, G | 1 |
| Liu, Y | 1 |
| Chen, X | 1 |
| Pan, M | 1 |
| Zhu, F | 1 |
| Fu, J | 1 |
| Fu, T | 1 |
| Gao, Z | 1 |
| Baldwin, DS | 1 |
| Tang, Z | 1 |
| Pollock, BG | 4 |
| Harmer, CJ | 3 |
| Cowen, PJ | 3 |
| Hilton, RC | 1 |
| Rengasamy, M | 1 |
| Mansoor, B | 1 |
| He, J | 1 |
| Mayes, T | 1 |
| Emslie, GJ | 2 |
| Porta, G | 1 |
| Clarke, GN | 1 |
| Wagner, KD | 1 |
| Birmaher, B | 1 |
| Keller, MB | 1 |
| Ryan, N | 1 |
| Shamseddeen, W | 1 |
| Asarnow, JR | 1 |
| Brent, DA | 1 |
| Yamada, M | 1 |
| Kawahara, Y | 1 |
| Kaneko, F | 1 |
| Kishikawa, Y | 1 |
| Sotogaku, N | 1 |
| Poppinga, WJ | 1 |
| Folgering, JH | 1 |
| Dremencov, E | 1 |
| Kawahara, H | 1 |
| Nishi, A | 1 |
| Anwar, MJ | 1 |
| Pillai, KK | 1 |
| Samad, A | 1 |
| Vohora, D | 1 |
| Weinstein, AM | 1 |
| Miller, H | 1 |
| Bluvstein, I | 1 |
| Rapoport, E | 1 |
| Schreiber, S | 1 |
| Bar-Hamburger, R | 1 |
| Kanaeva, LS | 1 |
| Dashkina, GK | 1 |
| Baltás, P | 1 |
| Ugurlu, TT | 1 |
| Acar, G | 1 |
| Karadag, F | 1 |
| Acar, F | 1 |
| Lotan, D | 1 |
| Versano, Z | 1 |
| Benatav, L | 1 |
| Armoza, S | 1 |
| Kately, N | 1 |
| Sayin, A | 1 |
| Derinöz, O | 1 |
| Yüksel, N | 1 |
| Şahin, S | 1 |
| Bolay, H | 1 |
| Benatti, C | 1 |
| Alboni, S | 1 |
| Blom, JM | 1 |
| Gandolfi, F | 1 |
| Mendlewicz, J | 1 |
| Brunello, N | 1 |
| Tascedda, F | 1 |
| Hestermann, D | 1 |
| Temel, Y | 1 |
| Blokland, A | 1 |
| Lim, LW | 1 |
| Vasa, RA | 1 |
| Carroll, LM | 1 |
| Nozzolillo, AA | 1 |
| Mahajan, R | 1 |
| Mazurek, MO | 1 |
| Bennett, AE | 1 |
| Wink, LK | 1 |
| Bernal, MP | 1 |
| Guilloux, JP | 1 |
| Bassi, S | 1 |
| Ding, Y | 1 |
| Walsh, C | 1 |
| Tseng, G | 1 |
| Cyranowski, JM | 1 |
| Sibille, E | 1 |
| Roohafza, H | 1 |
| Pourmoghaddas, Z | 1 |
| Saneian, H | 1 |
| Gholamrezaei, A | 1 |
| Savignac, HM | 1 |
| Kiely, B | 1 |
| Dinan, TG | 1 |
| Cryan, JF | 1 |
| Pettersson, R | 2 |
| Hagsäter, SM | 1 |
| Zohar, I | 2 |
| Dosoretz-Abittan, L | 1 |
| Shoham, S | 2 |
| Weinstock, M | 2 |
| Korendovych, IV | 1 |
| Svintsits'kyĭ, AS | 1 |
| Revenok, KM | 1 |
| Maliarov, SO | 1 |
| Mikheenko, Y | 1 |
| Shiba, Y | 1 |
| Sawiak, S | 1 |
| Braesicke, K | 1 |
| Cockcroft, G | 1 |
| Clarke, H | 1 |
| Kasahara, K | 1 |
| Hashimoto, S | 3 |
| Hattori, T | 1 |
| Kawasaki, K | 1 |
| Tsujita, R | 1 |
| Nakazono, O | 1 |
| Takao, K | 1 |
| Kawakubo, H | 1 |
| Nagatani, T | 1 |
| Schmidt, C | 1 |
| Studer, E | 1 |
| Hagsäter, M | 1 |
| Nissbrandt, H | 1 |
| Arnow, BA | 1 |
| Blasey, C | 1 |
| Rekshan, W | 1 |
| Schatzberg, AF | 1 |
| Etkin, A | 1 |
| Kulkarni, J | 1 |
| Luther, JF | 1 |
| Rush, AJ | 3 |
| Suliman, S | 1 |
| Seedat, S | 1 |
| Pingo, J | 1 |
| Sutherland, T | 1 |
| Zohar, J | 1 |
| Stein, DJ | 2 |
| Ehrlich, DE | 1 |
| Neigh, GN | 1 |
| Bourke, CH | 2 |
| Nemeth, CL | 1 |
| Hazra, R | 1 |
| Ryan, SJ | 1 |
| Rowson, S | 1 |
| Jairam, N | 1 |
| Sholar, CA | 1 |
| Rainnie, DG | 1 |
| Stowe, ZN | 1 |
| Owens, MJ | 2 |
| Alexopoulos, GS | 1 |
| Manning, K | 1 |
| Kanellopoulos, D | 1 |
| McGovern, A | 1 |
| Seirup, JK | 1 |
| Banerjee, S | 1 |
| Gunning, F | 1 |
| Kurhe, Y | 1 |
| Mahesh, R | 2 |
| McMahon, FJ | 1 |
| Liang, S | 1 |
| Wang, T | 1 |
| Hu, X | 1 |
| Luo, J | 1 |
| Li, W | 1 |
| Wu, X | 1 |
| Duan, Y | 1 |
| Jin, F | 1 |
| Zemdegs, J | 1 |
| Quesseveur, G | 1 |
| Jarriault, D | 1 |
| Pénicaud, L | 1 |
| Fioramonti, X | 1 |
| Guiard, BP | 1 |
| Lin, CC | 1 |
| Tung, CS | 1 |
| Liu, YP | 1 |
| Leonpacher, AK | 1 |
| Peters, ME | 1 |
| Drye, LT | 1 |
| Makino, KM | 1 |
| Newell, JA | 1 |
| Devanand, DP | 1 |
| Frangakis, C | 1 |
| Munro, CA | 1 |
| Mintzer, JE | 1 |
| Rosenberg, PB | 1 |
| Schneider, LS | 1 |
| Shade, DM | 1 |
| Weintraub, D | 1 |
| Yesavage, J | 1 |
| Lyketsos, CG | 1 |
| Porsteinsson, AP | 1 |
| Nobels, A | 1 |
| Geboes, K | 1 |
| Lemmens, GM | 1 |
| Ho, AM | 1 |
| Qiu, Y | 1 |
| Jia, YF | 1 |
| Aguiar, FS | 1 |
| Hinton, DJ | 1 |
| Karpyak, VM | 1 |
| Weinshilboum, RM | 1 |
| Choi, DS | 1 |
| Feger, BJ | 1 |
| Ashworth, M | 1 |
| Mabe, SK | 1 |
| Babyak, MA | 1 |
| Ionescu, DF | 1 |
| Shelton, RC | 1 |
| Baer, L | 1 |
| Meade, KH | 1 |
| Swee, MB | 1 |
| Fava, M | 3 |
| Papakostas, GI | 2 |
| Kim, JM | 1 |
| Kang, HJ | 1 |
| Bae, KY | 1 |
| Kim, SW | 1 |
| Shin, IS | 1 |
| Hong, YJ | 1 |
| Ahn, Y | 1 |
| Jeong, MH | 1 |
| Kang, H | 1 |
| Yoon, JS | 1 |
| Fitzpatrick, CM | 1 |
| Larsen, M | 1 |
| Madsen, LH | 1 |
| Caballero-Puntiverio, M | 1 |
| Pickering, DS | 1 |
| Clausen, RP | 1 |
| Andreasen, JT | 1 |
| Salehpour, F | 1 |
| Rasta, SH | 1 |
| Mohaddes, G | 1 |
| Sadigh-Eteghad, S | 1 |
| Salarirad, S | 1 |
| Kaminska, K | 1 |
| Rogoz, Z | 1 |
| Sprowles, JL | 1 |
| Hufgard, JR | 1 |
| Gutierrez, A | 1 |
| Bailey, RA | 1 |
| Jablonski, SA | 1 |
| Williams, MT | 1 |
| Vorhees, CV | 1 |
| John, A | 1 |
| Marchant, AL | 1 |
| Fone, DL | 1 |
| McGregor, JI | 1 |
| Dennis, MS | 1 |
| Tan, JO | 1 |
| Lloyd, K | 1 |
| Jukić, MM | 1 |
| Opel, N | 1 |
| Ström, J | 1 |
| Carrillo-Roa, T | 1 |
| Miksys, S | 1 |
| Novalen, M | 1 |
| Renblom, A | 1 |
| Sim, SC | 1 |
| Peñas-Lledó, EM | 1 |
| Courtet, P | 1 |
| Llerena, A | 1 |
| Baune, BT | 1 |
| de Quervain, DJ | 1 |
| Papassotiropoulos, A | 1 |
| Tyndale, RF | 1 |
| Binder, EB | 1 |
| Dannlowski, U | 1 |
| Ingelman-Sundberg, M | 1 |
| Murphy, SE | 1 |
| Yiend, J | 1 |
| Lester, KJ | 1 |
| Grillon, C | 2 |
| Chavis, C | 1 |
| Covington, MF | 1 |
| Pine, DS | 2 |
| Kellner, M | 1 |
| Muhtz, C | 1 |
| Demiralay, C | 1 |
| Husemann, J | 1 |
| Koelsch, W | 1 |
| Yassouridis, A | 1 |
| Wiedemann, K | 1 |
| Howland, RH | 1 |
| Wisniewski, SR | 2 |
| Trivedi, MH | 2 |
| Warden, D | 2 |
| Davis, LL | 1 |
| Balasubramani, GK | 2 |
| McGrath, PJ | 2 |
| Berman, SR | 1 |
| Inoue, T | 3 |
| Muraki, I | 2 |
| Koyama, T | 3 |
| Garg, R | 1 |
| Kumar, A | 2 |
| Deltheil, T | 1 |
| Tanaka, K | 1 |
| Reperant, C | 1 |
| Hen, R | 2 |
| David, DJ | 2 |
| Gardier, AM | 1 |
| Stewart, JW | 1 |
| Zisook, S | 1 |
| Cook, I | 1 |
| Nierenberg, AA | 1 |
| Lesser, I | 1 |
| John Rush, A | 1 |
| Stamouli, SS | 1 |
| Yfantis, A | 1 |
| Lamboussis, E | 1 |
| Liakouras, A | 1 |
| Lagari, V | 1 |
| Tzanakaki, M | 1 |
| Giailoglou, D | 1 |
| Legault, M | 1 |
| Parashos, IA | 1 |
| Muthusami, S | 1 |
| Basu, S | 1 |
| Dash, A | 1 |
| Perkins, AM | 1 |
| Ettinger, U | 1 |
| Davis, R | 1 |
| Foster, R | 1 |
| Williams, SC | 1 |
| Corr, PJ | 1 |
| Andó, RD | 1 |
| Adori, C | 1 |
| Kirilly, E | 1 |
| Molnár, E | 1 |
| Kovács, GG | 1 |
| Ferrington, L | 1 |
| Kelly, PA | 1 |
| Bagdy, G | 1 |
| Mombereau, C | 1 |
| Gur, TL | 1 |
| Onksen, J | 1 |
| Blendy, JA | 1 |
| Boulenger, JP | 1 |
| Hermes, A | 1 |
| Huusom, AK | 1 |
| Weiller, E | 1 |
| Lavretsky, H | 2 |
| Siddarth, P | 1 |
| Irwin, MR | 2 |
| Frank, E | 2 |
| Cassano, GB | 1 |
| Rucci, P | 1 |
| Thompson, WK | 1 |
| Kraemer, HC | 1 |
| Fagiolini, A | 1 |
| Maggi, L | 1 |
| Kupfer, DJ | 1 |
| Shear, MK | 1 |
| Houck, PR | 2 |
| Calugi, S | 1 |
| Grochocinski, VJ | 1 |
| Scocco, P | 1 |
| Buttenfield, J | 1 |
| Forgione, RN | 1 |
| Kayiran, S | 1 |
| Dursun, E | 1 |
| Dursun, N | 1 |
| Ermutlu, N | 1 |
| Karamürsel, S | 1 |
| Marchesi, C | 2 |
| Parenti, P | 1 |
| Aprile, S | 1 |
| Cabrino, C | 1 |
| De Panfilis, C | 2 |
| Pandey, DK | 1 |
| Katiyar, S | 1 |
| Kukade, G | 1 |
| Viyogi, S | 1 |
| Rudra, A | 1 |
| Larsen, K | 1 |
| Hannestad, J | 1 |
| DellaGioia, N | 1 |
| Ortiz, N | 1 |
| Pittman, B | 1 |
| Bhagwagar, Z | 2 |
| Cassimjee, N | 1 |
| Fouche, JP | 1 |
| Burnett, M | 1 |
| Lochner, C | 1 |
| Warwick, J | 1 |
| Dupont, P | 1 |
| Cloete, KJ | 1 |
| Carey, PD | 1 |
| Alstein, LL | 1 |
| Olmstead, RE | 1 |
| Ercoli, LM | 1 |
| Riparetti-Brown, M | 1 |
| Cyr, NS | 1 |
| Birkett, MA | 1 |
| Shinday, NM | 1 |
| Kessler, EJ | 1 |
| Meyer, JS | 1 |
| Ritchie, S | 1 |
| Rowlett, JK | 1 |
| Brown, HD | 1 |
| Amodeo, DA | 1 |
| Ragozzino, ME | 1 |
| Peruga, I | 1 |
| Hartwig, S | 1 |
| Merkler, D | 1 |
| Thöne, J | 1 |
| Hovemann, B | 1 |
| Juckel, G | 1 |
| Gold, R | 1 |
| Linker, RA | 1 |
| Park, HJ | 1 |
| Kim, EJ | 1 |
| Ku, JI | 1 |
| Woo, JM | 1 |
| Lee, SH | 1 |
| Chung, SK | 1 |
| Lee, SY | 1 |
| Kim, YR | 1 |
| Kang, EH | 1 |
| Lee, JH | 1 |
| Kim, JH | 1 |
| Yu, BH | 1 |
| Laux, G | 1 |
| Friede, M | 1 |
| Müller, WE | 1 |
| Lenze, EJ | 2 |
| Dixon, D | 1 |
| Nowotny, P | 1 |
| Lotrich, FE | 1 |
| Doré, PM | 1 |
| Hinrichs, AL | 1 |
| Butters, MA | 2 |
| Pardini, M | 1 |
| Capello, E | 1 |
| Krueger, F | 1 |
| Mancardi, G | 1 |
| Uccelli, A | 1 |
| Karaiskos, D | 1 |
| Tzavellas, E | 1 |
| Spengos, K | 1 |
| Vassilopoulou, S | 1 |
| Paparrigopoulos, T | 1 |
| Mead, GE | 1 |
| Hsieh, CF | 1 |
| Lee, R | 1 |
| Kutlubaev, MA | 1 |
| Claxton, A | 1 |
| Hankey, GJ | 1 |
| Hackett, ML | 1 |
| Stryjer, R | 1 |
| Dambinsky, Y | 1 |
| Timinsky, I | 1 |
| Green, T | 1 |
| Kotler, M | 1 |
| Spivak, B | 1 |
| Steiner, AR | 1 |
| Petkus, AJ | 1 |
| Nguyen, H | 1 |
| Wetherell, JL | 1 |
| Flandreau, EI | 1 |
| Ressler, KJ | 1 |
| Vale, WW | 1 |
| Nemeroff, CB | 1 |
| Delacerda, A | 1 |
| Reichenberg, JS | 1 |
| Magid, M | 1 |
| Baumgartner, JL | 1 |
| Crismon, ML | 1 |
| Perrett, DI | 1 |
| Völlm, BA | 1 |
| Goodwin, GM | 1 |
| Giorgi, O | 1 |
| Piras, G | 1 |
| Lecca, D | 1 |
| Hansson, S | 1 |
| Driscoll, P | 1 |
| Corda, MG | 1 |
| Tsang, SW | 1 |
| Lai, MK | 1 |
| Francis, PT | 1 |
| Wong, PT | 1 |
| Spence, I | 1 |
| Esiri, MM | 1 |
| Keene, J | 1 |
| Hope, T | 1 |
| Chen, CP | 1 |
| Sánchez, C | 2 |
| Gruca, P | 1 |
| Bien, E | 1 |
| Papp, M | 1 |
| Shlik, J | 1 |
| Maron, E | 1 |
| Tru, I | 1 |
| Aluoja, A | 1 |
| Vasar, V | 1 |
| Romano, P | 1 |
| van Beek, N | 1 |
| Cucchi, M | 1 |
| Biffi, S | 1 |
| Perna, G | 1 |
| Menza, M | 1 |
| Marin, H | 1 |
| Kaufman, K | 1 |
| Mark, M | 1 |
| Lauritano, M | 1 |
| Bose, A | 1 |
| Neznanov, NG | 1 |
| Bortsov, AV | 1 |
| Sandager, M | 1 |
| Nielsen, ND | 1 |
| Stafford, GI | 1 |
| van Staden, J | 1 |
| Jäger, AK | 1 |
| Furmark, T | 1 |
| Appel, L | 1 |
| Michelgård, A | 1 |
| Wahlstedt, K | 1 |
| Ahs, F | 1 |
| Zancan, S | 1 |
| Jacobsson, E | 1 |
| Flyckt, K | 1 |
| Grohp, M | 1 |
| Bergström, M | 1 |
| Pich, EM | 1 |
| Nilsson, LG | 1 |
| Bani, M | 1 |
| Långström, B | 1 |
| Fredrikson, M | 1 |
| Massé, F | 1 |
| Hascoët, M | 1 |
| Bourin, M | 1 |
| Tack, J | 1 |
| Broekaert, D | 1 |
| Fischler, B | 1 |
| Van Oudenhove, L | 1 |
| Gevers, AM | 1 |
| Janssens, J | 1 |
| Nedostup, AV | 1 |
| Fedorova, VI | 1 |
| Linevich, AIu | 1 |
| Pukhal'skaia, TG | 1 |
| Toropina, GG | 1 |
| Kudrin, VS | 1 |
| Klodt, PM | 1 |
| Rampello, L | 1 |
| Alvano, A | 1 |
| Raffaele, R | 1 |
| Malaguarnera, M | 1 |
| Vecchio, I | 1 |
| Izumi, T | 1 |
| Kitaichi, Y | 1 |
| Nakagawa, S | 1 |
| Hsiao, SY | 1 |
| Cherng, CF | 1 |
| Yang, YK | 1 |
| Yeh, TL | 1 |
| Yu, L | 1 |
| Csoka, AB | 1 |
| Shipko, S | 1 |
| Hogg, S | 1 |
| Michan, L | 1 |
| Jessa, M | 1 |
| Selby, P | 1 |
| Levenson, J | 1 |
| Klemenhagen, KC | 1 |
| Holick, KA | 1 |
| Saxe, MD | 1 |
| Mendez, I | 1 |
| Santarelli, L | 1 |
| Craig, DA | 1 |
| Zhong, H | 1 |
| Swanson, CJ | 1 |
| Hegde, LG | 1 |
| Ping, XI | 1 |
| Dong, D | 1 |
| Marzabadi, MR | 1 |
| Gerald, CP | 1 |
| Castle, M | 1 |
| Libby, GW | 1 |
| Saghafi, R | 1 |
| Brown, C | 1 |
| Cyranowski, J | 1 |
| Dew, MA | 1 |
| Gildengers, A | 1 |
| Karp, JF | 1 |
| Lotrich, F | 1 |
| Martire, L | 1 |
| Mazumdar, S | 1 |
| Miller, MD | 1 |
| Mulsant, BH | 1 |
| Weber, E | 1 |
| Whyte, E | 1 |
| Morse, J | 1 |
| Stack, J | 1 |
| Bensasi, S | 1 |
| Reynolds, CF | 1 |
| Jochum, T | 1 |
| Boettger, MK | 1 |
| Wigger, A | 1 |
| Beiderbeck, D | 1 |
| Neumann, ID | 1 |
| Landgraf, R | 1 |
| Sauer, H | 1 |
| Bär, KJ | 1 |
| Mällo, T | 2 |
| Matrov, D | 1 |
| Herm, L | 1 |
| Eller, M | 2 |
| Rinken, A | 1 |
| Keuthen, NJ | 1 |
| Jameson, M | 1 |
| Loh, R | 1 |
| Deckersbach, T | 1 |
| Wilhelm, S | 1 |
| Dougherty, DD | 1 |
| Jerome, L | 1 |
| Gentile, S | 1 |
| Vozzi, F | 1 |
| Tõnissaar, M | 1 |
| Häidkind, R | 1 |
| Kuan, WL | 1 |
| Zhao, JW | 1 |
| Barker, RA | 1 |
| Cantoni, A | 1 |
| Giannelli, MR | 1 |
| Maggini, C | 1 |
| Wong, WM | 1 |
| Hasemann, S | 1 |
| Schwarz, M | 1 |
| Zill, P | 1 |
| Koller, G | 1 |
| Soyka, M | 1 |
| Preuss, UW | 1 |
| Spindelegger, C | 1 |
| Lanzenberger, R | 1 |
| Wadsak, W | 1 |
| Mien, LK | 1 |
| Stein, P | 1 |
| Mitterhauser, M | 1 |
| Moser, U | 1 |
| Holik, A | 1 |
| Pezawas, L | 1 |
| Kletter, K | 1 |
| Kasper, S | 1 |
| Höschl, C | 1 |
| Svestka, J | 1 |
| Bigos, KL | 1 |
| Aizenstein, HJ | 1 |
| Fisher, PM | 1 |
| Bies, RR | 1 |
| Hariri, AR | 1 |
| Griebel, G | 1 |
| Moreau, JL | 1 |
| Jenck, F | 1 |
| Misslin, R | 1 |
| Martin, JR | 1 |
| Meier, E | 1 |
| Kulikov, A | 1 |
| Aguerre, S | 1 |
| Berton, O | 1 |
| Ramos, A | 1 |
| Mormede, P | 1 |
| Chaouloff, F | 1 |
| Matto, V | 3 |
| Allikmets, L | 3 |
| Neuger, J | 1 |
| Wistedt, B | 1 |
| Sinner, B | 1 |
| Aberg-Wistedt, A | 1 |
| Stain-Malmgren, R | 1 |
| Naranjo, CA | 1 |
| Knoke, DM | 1 |
| Bremner, KE | 1 |
| Schaller, JL | 1 |
| Behar, D | 1 |
| Pruus, K | 1 |
| Vaarmann, A | 1 |
| Rudissaar, R | 1 |
| Durcan, MJ | 2 |
| Lister, RG | 2 |
| Eckardt, MJ | 2 |
| Linnoila, M | 2 |
| Dufour, H | 1 |
| Bouchacourt, M | 1 |
| Thermoz, P | 1 |
| Viala, A | 1 |
| Phak Rop, P | 1 |
| Gouezo, F | 1 |
| Durand, A | 1 |
| Høpfner Petersen, HE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety[NCT02818751] | 84 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| International Study to Predict Optimised Treatment - in Depression[NCT00693849] | Phase 4 | 2,688 participants (Anticipated) | Interventional | 2008-09-30 | Active, not recruiting | ||
| Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)[NCT00018902] | Phase 2/Phase 3 | 334 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| [NCT00300313] | 450 participants (Anticipated) | Interventional | 2005-06-30 | Completed | |||
| Exercise and Pharmacotherapy for Anxiety in Cardiac Patients[NCT02516332] | 128 participants (Actual) | Interventional | 2015-12-31 | Completed | |||
| A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatmen[NCT00633399] | Phase 2 | 458 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| Caring for Caregivers With Mind-body Exercise[NCT04019301] | 47 participants (Actual) | Interventional | 2019-04-22 | Active, not recruiting | |||
| Brain Connectivity and Response to Tai Chi in Geriatric Depression[NCT02460666] | 220 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke[NCT02683213] | Phase 3 | 1,500 participants (Actual) | Interventional | 2014-10-20 | Completed | ||
| A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)[NCT00271596] | Phase 2 | 33 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome[NCT00583128] | Phase 2 | 117 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To assess baroreflex sensitivity (BRS), beat-by-beat systolic blood pressure (SBP) and heart rate (HR) were collected using the Nexfin noninvasive BP monitor (Bmeye, Amsterdam, Netherlands). BRS was estimated from the magnitude of the transfer function relating R-R interval oscillations to SBP oscillations across the 0.07 to 0.1299 Hz, or low frequency band. (NCT02516332)
Timeframe: Baseline, 3 months
| Intervention | ms/mm Hg (Least Squares Mean) |
|---|---|
| Supervised Aerobic Exercise | 1.2 |
| Lexapro | 1.3 |
| Placebo | 1.5 |
To quantify heart rate variability (HRV), an electrocardiogram was recorded for 24-hours using the 3-channel DigiTrak XT Holter recorder (Philips Healthcare, Andover, Massachusetts). Electrocardiographic data were downloaded and edited using the Philips Zymed Holter analysis software (2010 Plus/1810 series) and HRV was estimated from the standard deviation of the normal-to-normal R-R intervals (SDNN). (NCT02516332)
Timeframe: Baseline, 3 months
| Intervention | msec (Least Squares Mean) |
|---|---|
| Supervised Aerobic Exercise | -0.3 |
| Lexapro | -8.7 |
| Placebo | -1.1 |
The Hospital Anxiety and Depression Scale, Anxiety, is a 7-item subscale with scores ranging from 0-21, with higher scores indicating more anxiety. (NCT02516332)
Timeframe: Baseline, 3 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Supervised Aerobic Exercise | -3.9 |
| Lexapro | -5.7 |
| Placebo | -3.5 |
High-sensitivity C-reactive protein was quantified by ELISA (LabCorp). Values >10 mg/L were truncated at 10 to account for acute inflammatory processes that may have skewed the distribution of this blood marker. (NCT02516332)
Timeframe: Baseline, 3 months
| Intervention | ug/ml (Least Squares Mean) |
|---|---|
| Supervised Aerobic Exercise | -0.2 |
| Lexapro | 0.1 |
| Placebo | -0.3 |
Urinary catecholamines, an index of sympathetic nervous system (SNS) activity, served as a biomarker of anxiety. Urinary concentrations of epinephrine (EPI) and norepinephrine (NE) were determined by high-pressure liquid chromatography (HPLC) with electrochemical detection (LabCorp). A composite 24-hr catecholamines z-score is presented. The z-score is the raw score minus the population mean, divided by the population standard deviation. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean. (NCT02516332)
Timeframe: Baseline, 3 months
| Intervention | z-score (Least Squares Mean) |
|---|---|
| Supervised Aerobic Exercise | 0.05 |
| Lexapro | -0.24 |
| Placebo | 0.36 |
Endothelial function, assessed by Flow-Mediated Dilation (FMD), was determined from longitudinal B-mode ultrasound images of the brachial artery. Images were obtained using an Acuson (Mountain View, California) Aspen ultrasound platform with an 11-MHz linear-array transducer after 10 min of supine relaxation and during reactive hyperemia, induced by the inflation of a forearm pneumatic occlusion cuff to suprasystolic pressure (about 200 mm Hg) and subsequent deflation after 5 min. FMD was defined as the maximum percentage change in arterial diameter relative to resting baseline from 10 to 120 s after deflation of the occlusion cuff. (NCT02516332)
Timeframe: Baseline, 3 months
| Intervention | percentage of dilation (Least Squares Mean) |
|---|---|
| Supervised Aerobic Exercise | 0.7 |
| Lexapro | 0.5 |
| Placebo | 0.5 |
Lipids were obtained from fasting blood samples and assays were measured enzymatically (LabCorp). (NCT02516332)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Least Squares Mean) | ||
|---|---|---|---|
| Total Cholesterol | LDL | HDL | |
| Lexapro | -15.3 | -9.8 | 3.4 |
| Placebo | -31.6 | -19.3 | 7.2 |
| Supervised Aerobic Exercise | -28.2 | -18.6 | 6.3 |
This will involve looking at the change in HAM-D 17 scores during phase 2. For HAMD-17 the minimum is 0, the maximum is 52, and greater scores represent more symptoms. (NCT00633399)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Ziprasidone + Escitalopram | -6.4 |
| Placebo + Escitalopram | -3.3 |
A secondary outcome measure will be remission rates (HAM-D 17 scores of less than 8) after treatment phase 2.. A remitted will be a patient with a final score of 7 or less on the HAMD-17 during phase 2. (NCT00633399)
Timeframe: 8 weeks
| Intervention | Percentage of patients (Number) |
|---|---|
| Ziprasidone + Escitalopram | 38 |
| Placebo + Escitalopram | 30 |
The primary outcome measure will be response rates (50% decrease in HAM-D-17 scores) during phase 2. A responder will be a patient who experiences a 50% or greater decrease in symptoms according to the HAM-D-17 during phase 2. (NCT00633399)
Timeframe: 8 Weeks
| Intervention | Percentage of patients (Number) |
|---|---|
| Ziprasidone + Escitalopram | 35.2 |
| Placebo + Escitalopram | 20.5 |
"Neuropsychological battery of tests which included the following domains:~Attention/Executive Function (Trail Making Test A and B, Stroop Interference [Golden version])~Raw scores were transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across both arms) is zero for each test score. These z-scores were then averaged within each neuropsychological domain to produce composite scores. Higher scores are indicative of better performance." (NCT02460666)
Timeframe: Measured at baseline and 3 months
| Intervention | z-score (Mean) |
|---|---|
| Tai-Chi Chih Classes | -0.04 |
| Health Education and Wellness Classes | 0.03 |
"Neuropsychological battery of tests which included the following domains:~Delayed Recall (CVLT-II [Long-Delay Free Recall], Rey-Osterrieth Complex Figure Test [30-minute Delayed Recall])~Raw scores were transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across both arms) is zero for each test score. These z-scores were then averaged within each neuropsychological domain to produce composite scores. Higher scores are indicative of better performance." (NCT02460666)
Timeframe: Measured at baseline and 3 months
| Intervention | z-score (Mean) |
|---|---|
| Tai-Chi Chih Classes | -0.15 |
| Health Education and Wellness Classes | -0.002 |
Clinician administered scale measures severity of depressive symptoms. This measure includes 24 items. Response options vary item to item and include the following ranges: [0-2], [0-3], and [0-4]. A score of 0 suggests absence of symptoms and/or difficulties and higher scores represent more severe difficulties. Possible overall score range [0-74], higher scores representing more severe difficulties. (NCT02460666)
Timeframe: Measured at baseline and 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| Tai-Chi Chih Classes | -9.27 |
| Health Education and Wellness Classes | -9.40 |
"Neuropsychological battery of tests which included the following domains:~Language (Controlled Oral Word Association test [FAS], Animal Fluency, and Boston Naming Test)~Raw scores were transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across both arms) is zero for each test score. These z-scores were then averaged within each neuropsychological domain to produce composite scores. Higher scores are indicative of better performance." (NCT02460666)
Timeframe: Measured at baseline and 3 months
| Intervention | z-score (Mean) |
|---|---|
| Tai-Chi Chih Classes | 0.03 |
| Health Education and Wellness Classes | -0.12 |
The UKU (Udvalg for Kliniske Undersogelser) Side Effect Rating Scale organizes symptoms into 4 categories (i.e., Psychic, Neurologic, Autonomic, Other) containing 8-19 symptoms each. Each symptom receives a score for degree and causal relationship. Degree is scored between 0-3 with higher scores being more severe. Causal relationship is scored as improbable, possible, or probable. (NCT02460666)
Timeframe: Measured at 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tai-Chi Chih Classes | 4 |
| Health Education and Wellness Classes | 3 |
Full Scale Name: The Executive Composite Score (ECS). Definition: Subscales were averaged to compute this composite total score. The ECS is the weighted average of performance on 6 subtests of executive function, including (1) the Controlled Oral Word Association Test, (2) Symbol Digit Modalities test; (3) Stroop Color Word Test (Interference Trial), (4) Trail Making test (Part B), (5) Letter-Number Sequencing, and (6) Animal Naming. Construct Measured: Thinking tasks involving planning, working memory, attention, problem solving, verbal reasoning, inhibition, mental flexibility, and task switching. ECS Scale Range: The ECS score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on executive functioning tasks. Change Calculation Details: Compares change in executive functioning performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.005 |
| Placebo | 0.172 |
Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: Compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.67 |
| Placebo | 1.23 |
Full Scale Name: Letter Number Sequencing (LNS) subtest from the Wechsler Adult Intelligence Scale (WAIS) third edition. Definition: LNS is a task that requires the reordering of an initially unordered set of letters and numbers. Construct Measured: Working memory. LNS Score Range: Raw scores may range from 0 to 21, where lower scores indicate poorer performance in working memory. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.113 |
| Placebo | 0.225 |
Semantic Fluency Score. Definition: The Semantic Fluency Score is the number of words a person can produce given a category, including naming (1) Animal names, (2) Fruit names, (3) Boy names, (4) Girl names, and (5) Vegetable names. Construct Measured: Working memory and verbal initiation. Scale Range: The Semantic Fluency Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on working memory tasks. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) where patients named fruit names to the weighted average of visits 5 (week 12) & 6 (week 15) where patients named girl names and vegetable names respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.386 |
| Placebo | 0.664 |
"Full Scale Name: Stroop Interference subtest from The Stroop Color and Word Test. Definition: Participants are asked to name the ink color in which a word is printed when the word itself (which is irrelevant to the task) is the name of a different color rather than the same color. For example, participants may be asked to say red to the word blue printed in red ink. Constructs Measured: Selective attention, response inhibition, cognitive flexibility, and processing speed. Scale Range: The Stroop Interference score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.256 |
| Placebo | -0.046 |
Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: This analysis was restricted to a subgroup and, accordingly, does not reflect the total number of participants as reported in the Participant Flow. This analysis compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.10 |
| Placebo | 1.50 |
Full Scale Name: The Symbol Digit Modalities Test (SDMT). Definition: The SDMT screens for organic cerebral dysfunction by having the examinee use a reference key to pair specific numbers with given geometric figures in 90 seconds. Construct Measured: Attention, processing speed, and working memory. SDMT Scale Range: Raw scores may range from 0 to 110, where lower scores indicate poorer performance. Change Calculation Details: Compares change in performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.227 |
| Placebo | -0.170 |
Full Scale Name: The Total Functional Capacity (TFC) subscale from the Unified Huntington's Disease Rating Scale (UHDRS). Definition: The TFC is a score that classifies five stages of Huntington's Disease and five levels of function in the domains of workplace, finances, domestic chores, activities of daily living and requirements for unskilled or skilled care. Construct Measured: Activities of Daily Living. Scale Range: The TFC score ranges from 0 to 13, where lower scores indicate poorer performance in activities of daily living. Change Calculation Details: Compares change in TFC performance from Baseline (week -4) to the weighted average of visits 4 (week 6) and 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.54 |
| Placebo | -0.06 |
"Full Scale Name: Trail Making Test Part B (TMT-B). Definition: The TMT-B test requires participants to connect-the-dots of 25 consecutive targets on a sheet of paper where the subject alternates between numbers and letters, going in both numerical and alphabetical order. Constructs Measured: Attention, set shifting, and processing speed. Scale range: The TMT-B score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.087 |
| Placebo | 0.405 |
Full Scale Name: The Verbal Fluency Score (VFC). Definition: The VFC is the number of words a person can produce given a letter, including (1) Naming words that start with F, A, and S; (2) naming words that start with K, W, and R; (3) naming words that start with V, I, and P; (4) naming words that start with O, G, and B; (5) naming words that start with E, N, and T; and (6) naming words that start with J, C, and S. Construct Measured: Verbal initiation and flexibility. Scale Range: The Verbal Fluency Composite Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in verbal initiation and flexibility from visit 2 (week 0) where patients named words starting with O, G, and B to the weighted average of visits 5 (week 12) and 6 (week 15) where patients named words starting with E, N, and T, and J, C, and S respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.140 |
| Placebo | 0.071 |
10 reviews available for citalopram and Anxiety
| Article | Year |
|---|---|
Safety and Efficacy of SSRIs in Improving Poststroke Recovery: A Systematic Review and Meta-Analysis.
Topics: Anxiety; Citalopram; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Stroke; United Sta | 2022 |
Mood disorders and outcomes in lung cancer patients undergoing surgery: a brief summery.
Topics: Anxiety; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Humans; Lu | 2020 |
Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression.
Topics: Adult; Akathisia, Drug-Induced; Anxiety; Citalopram; Clinical Trials as Topic; Depressive Disorder; | 2017 |
What are the risks associated with different Selective Serotonin Re-uptake Inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence.
Topics: Adult; Anxiety; Citalopram; Depression; Female; Humans; Paroxetine; Pregnancy; Pregnancy Complicatio | 2017 |
Meta-analysis: Second generation antidepressants and headache.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Citalopram; Depression; Double- | 2018 |
'It's the way that you look at it'--a cognitive neuropsychological account of SSRI action in depression.
Topics: Adaptation, Psychological; Animals; Antidepressive Agents; Anxiety; Citalopram; Cognitive Behavioral | 2013 |
A systematic review of treatments for anxiety in youth with autism spectrum disorders.
Topics: Adolescent; Anxiety; Child; Child Development Disorders, Pervasive; Citalopram; Clinical Trials as T | 2014 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
[A new quality of the therapy of anxiety and depression--escitalopram].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antidepressive Agents, Second-Generation; Anxie | 2005 |
Escitalopram for the treatment of major depression and anxiety disorders.
Topics: Antidepressive Agents; Anxiety; Citalopram; Clinical Trials as Topic; Depressive Disorder, Major; Hu | 2008 |
51 trials available for citalopram and Anxiety
| Article | Year |
|---|---|
Citalopram Did Not Significantly Improve Anxiety in Children with Autism Spectrum Disorder Undergoing Treatment for Core Symptoms: Secondary Analysis of a Trial to Reduce Repetitive Behaviors.
Topics: Adolescent; Anxiety; Anxiety Disorders; Autism Spectrum Disorder; Child; Citalopram; Humans; Selecti | 2022 |
Longer term benefits of exercise and escitalopram in the treatment of anxiety in patients with coronary heart disease: Six month follow-up of the UNWIND randomized clinical trial.
Topics: Anxiety; Citalopram; Coronary Disease; Escitalopram; Exercise; Follow-Up Studies; Humans; Selective | 2022 |
A randomized placebo-controlled trial examining the effects of escitalopram on neuroticism and state anxiety in a nonclinical sample.
Topics: Adult; Anxiety; Citalopram; Female; Humans; Male; Neuroticism; Psychiatric Status Rating Scales; Sur | 2019 |
Lavender and dodder combined herbal syrup versus citalopram in major depressive disorder with anxious distress: A double-blind randomized trial.
Topics: Anxiety; Citalopram; Cuscuta; Depressive Disorder, Major; Double-Blind Method; Humans; Iran; Lavandu | 2020 |
Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial.
Topics: Adolescent; Amygdala; Anxiety; Anxiety Disorders; Child; Citalopram; Double-Blind Method; Female; Hu | 2021 |
Prophylactic SSRI treatment for women suffering from mood and anxiety symptoms undergoing in vitro fertilization-a prospective placebo-controlled study.
Topics: Adult; Affect; Anxiety; Citalopram; Double-Blind Method; Female; Fertilization in Vitro; Humans; Mid | 2019 |
Heart rate variability as a biomarker of anxious depression response to antidepressant medication.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety; Biomarkers; Citalopram; Depression; Depress | 2019 |
Dimensions of anxiety in Major depressive disorder and their use in predicting antidepressant treatment outcome: an iSPOT-D report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety; Citalopram; Cognition; Depressive Disorder, | 2020 |
Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
Topics: Adolescent; Anxiety; Attention Deficit and Disruptive Behavior Disorders; Behavioral Symptoms; Cital | 2013 |
Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study.
Topics: Adult; Anxiety; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Dou | 2014 |
[The formation of clinical and functional remission during the treatment of non-psychotic depression with escitalopram (lenuxin)].
Topics: Adolescent; Adult; Aged; Anxiety; Citalopram; Depressive Disorder; Female; Humans; Male; Middle Aged | 2013 |
Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression.
Topics: Adult; Anxiety; Biomarkers; Case-Control Studies; Citalopram; Combined Modality Therapy; Depressive | 2015 |
Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial.
Topics: Abdominal Pain; Adolescent; Antidepressive Agents, Second-Generation; Anxiety; Child; Citalopram; De | 2014 |
[Psychopharmacological approach with the usage of selective serotonin reuptake inhibitors in functional dyspepsia treatment].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anxiety; Citalopram; Depression; Drug Therapy, Combination | 2014 |
Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.
Topics: Adult; Antidepressive Agents; Anxiety; Citalopram; Cyclohexanols; Depressive Disorder; Depressive Di | 2015 |
Escitalopram in the prevention of posttraumatic stress disorder: a pilot randomized controlled trial.
Topics: Adult; Analysis of Variance; Anxiety; Citalopram; Depression; Double-Blind Method; Drug Monitoring; | 2015 |
Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study.
Topics: Alzheimer Disease; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Delusions; Female; | 2016 |
Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trial.
Topics: Adult; Anxiety; Biomarkers; Citalopram; Coronary Artery Disease; Diagnostic and Statistical Manual o | 2016 |
Ziprasidone augmentation for anxious depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety; Ci | 2016 |
Determinants and escitalopram treatment effects on suicidal ideation in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies.
Topics: Acute Coronary Syndrome; Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Cross- | 2016 |
Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers.
Topics: Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Anxiety; Attention; Citalopram; Decision | 2009 |
Two-week treatment with the selective serotonin reuptake inhibitor citalopram reduces contextual anxiety but not cued fear in healthy volunteers: a fear-potentiated startle study.
Topics: 5-Hydroxytryptophan; Acoustic Stimulation; Adult; Analysis of Variance; Anxiety; Citalopram; Cues; D | 2009 |
The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype.
Topics: Adolescent; Adult; Analysis of Variance; Anxiety; Citalopram; Cross-Over Studies; Double-Blind Metho | 2009 |
Do atypical features affect outcome in depressed outpatients treated with citalopram?
Topics: Adolescent; Adult; Age of Onset; Aged; Anxiety; Citalopram; Depressive Disorder, Major; Female; Huma | 2010 |
Effects of Lorazepam and citalopram on human defensive reactions: ethopharmacological differentiation of fear and anxiety.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Avoidance Learning; C | 2009 |
Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Depressive D | 2010 |
Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety; Caregivers; Citalopram; | 2010 |
Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy.
Topics: Adult; Affect; Anxiety; Citalopram; Depressive Disorder, Major; Female; Humans; Male; Predictive Val | 2011 |
Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial.
Topics: Adolescent; Adult; Anxiety; Citalopram; Depression; Female; Fibromyalgia; Humans; Middle Aged; Neuro | 2010 |
Citalopram reduces endotoxin-induced fatigue.
Topics: Adult; Anxiety; Behavior; Citalopram; Cytokines; Depression; Double-Blind Method; Endotoxins; Fatigu | 2011 |
Complementary use of tai chi chih augments escitalopram treatment of geriatric depression: a randomized controlled trial.
Topics: Aged; Anxiety; C-Reactive Protein; Citalopram; Cognition; Combined Modality Therapy; Depressive Diso | 2011 |
Psychological characteristics of early remitters in patients with panic disorder.
Topics: Adult; Agoraphobia; Anxiety; Citalopram; Female; Humans; Male; Panic Disorder; Psychiatric Status Ra | 2012 |
Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors.
Topics: Aged; Aged, 80 and over; Anxiety; Attention; Citalopram; Double-Blind Method; Female; Humans; Male; | 2013 |
Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue.
Topics: Activities of Daily Living; Adult; Aged; Antidepressive Agents; Anxiety; Citalopram; Depression; Dul | 2012 |
Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
Topics: Adult; Antipsychotic Agents; Anxiety; Citalopram; Compulsive Behavior; Diagnostic and Statistical Ma | 2013 |
Acute SSRI administration affects the processing of social cues in healthy volunteers.
Topics: Adult; Affect; Anxiety; Citalopram; Cues; Double-Blind Method; Emotions; Facial Expression; Female; | 2003 |
Citalopram challenge in social anxiety disorder.
Topics: Adolescent; Adult; Anxiety; Behavior; Citalopram; Cross-Over Studies; Double-Blind Method; Female; H | 2004 |
Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition.
Topics: Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Cognition; Depression; Disabili | 2004 |
Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting.
Topics: Adult; Anxiety; Citalopram; Depressive Disorder, Major; Disability Evaluation; Drug Administration S | 2005 |
Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo.
Topics: Adult; Anxiety; Cerebrovascular Circulation; Citalopram; Double-Blind Method; Female; Humans; Male; | 2005 |
A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Cross-Ov | 2006 |
[Anxiodepressive and neuromediatory disorders in hypertensive patients. Effects of cypramil therapy].
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antihypertensive Agents; Anxiety; Citalopram; | 2005 |
New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram.
Topics: Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Depression; Dose-Response Relat | 2006 |
A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study.
Topics: Adolescent; Adult; Analysis of Variance; Anxiety; Citalopram; Cross-Over Studies; Double-Blind Metho | 2007 |
Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder.
Topics: Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Depressive Disorder, Major; Fem | 2007 |
Open-label escitalopram treatment for pathological skin picking.
Topics: Adult; Anxiety; Citalopram; Comorbidity; Depression; Dose-Response Relationship, Drug; Female; Human | 2007 |
Effect of pharmacological treatment on temperament and character in panic disorder.
Topics: Adult; Anxiety; Character; Citalopram; Female; Follow-Up Studies; GABA Modulators; Humans; Lorazepam | 2008 |
Citalopram neuropharmacological challenge in alcohol-dependent patients and controls: pharmacogenetic, endocrine and psychobehavioral results.
Topics: Adrenocorticotropic Hormone; Adult; Alcoholism; Alleles; Antidepressive Agents; Anxiety; Behavior; C | 2008 |
Acute 5-HT reuptake blockade potentiates human amygdala reactivity.
Topics: Adult; Akathisia, Drug-Induced; Amygdala; Anxiety; Brain Chemistry; Citalopram; Cross-Over Studies; | 2008 |
Variations in response to citalopram in men and women with alcohol dependence.
Topics: Adult; Alcoholism; Anxiety; Citalopram; Depression; Female; Humans; Male; Prospective Studies; Selec | 2000 |
Citalopram--a highly selective 5-HT uptake inhibitor--in the treatment of depressed patients.
Topics: Adult; Aged; Anxiety; Citalopram; Clinical Trials as Topic; Depressive Disorder; Female; Humans; Mal | 1987 |
114 other studies available for citalopram and Anxiety
| Article | Year |
|---|---|
Complex Effects of Sertraline and Citalopram on In Vitro Murine Breast Cancer Proliferation and on In Vivo Progression and Anxiety Level.
Topics: Animals; Anxiety; Cell Proliferation; Citalopram; Mice; Neoplasms; Selective Serotonin Reuptake Inhi | 2022 |
Prenatal exposure of citalopram elicits depression-like and anxiety-like behaviors and alteration of morphology and protein expression of medial prefrontal cortex in young adult mice.
Topics: Animals; Anxiety; Citalopram; Depression; Depressive Disorder, Major; Female; Male; Mice; Mice, Inbr | 2022 |
Effect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice.
Topics: Animals; Anxiety; Citalopram; Male; Mice; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2022 |
The effects of citalopram, SB-334867 and orexin-1, alone or in various combinations, on the anxiogenic-like effects of REM sleep deprivation in male mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Citalopram; Male; Maze Learning; Mice; Orexin Receptor Antago | 2022 |
The effect of nicotine on antidepressant and anxiolytic responses induced by citalopram and citicoline in mice.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Citalopram; Cytidine Diphosphate Choli | 2023 |
Attenuation of auditory mismatch negativity in serotonin transporter knockout mice with anxiety-related behaviors.
Topics: Animals; Anxiety; Auditory Cortex; Behavior, Animal; Citalopram; Disease Models, Animal; Evoked Pote | 2020 |
Gynecomastia Associated With Citalopram.
Topics: Adult; Anxiety; Citalopram; Gynecomastia; Humans; Male; Selective Serotonin Reuptake Inhibitors | 2019 |
Synergistic effect between citalopram and citicoline on anxiolytic effect in non-sensitized and morphine-sensitized mice: An isobologram analysis.
Topics: Analgesics, Opioid; Animals; Anti-Anxiety Agents; Anxiety; Citalopram; Cytidine Diphosphate Choline; | 2020 |
Antidepressant treatment strategy with an early onset of action improves the clinical outcome in patients with major depressive disorder and high anxiety: a multicenter and 6-week follow-up study.
Topics: Antidepressive Agents; Anxiety; Citalopram; Depressive Disorder, Major; Fluoxetine; Fluvoxamine; Fol | 2020 |
Synergistic antidepressant-like effect of capsaicin and citalopram reduces the side effects of citalopram on anxiety and working memory in rats.
Topics: Amitriptyline; Animals; Antidepressive Agents; Anxiety; Capsaicin; Citalopram; Depression; Dose-Resp | 2020 |
Trait Anxiety Mediated by Amygdala Serotonin Transporter in the Common Marmoset.
Topics: Amygdala; Animals; Anxiety; Behavior, Animal; Callithrix; Citalopram; Emotions; Exploratory Behavior | 2020 |
Escitalopram-Induced Hair Loss.
Topics: Adult; Alopecia; Anxiety; Citalopram; Depression; Female; Humans; Selective Serotonin Reuptake Inhib | 2020 |
Expression and impact of Lsamp neural adhesion molecule in the serotonergic neurotransmission system.
Topics: Animals; Anxiety; Behavior, Animal; Cell Adhesion Molecules, Neuronal; Citalopram; Elevated Plus Maz | 2020 |
Acute Citalopram administration modulates anxiety in response to the context associated with a robotic stimulus in zebrafish.
Topics: Animals; Anxiety; Avoidance Learning; Citalopram; Conditioning, Classical; Dose-Response Relationshi | 2021 |
Prolonged treatment of COVID-19 pneumonia with high-flow nasal oxygen: A story of oxygen and resilience.
Topics: Anti-Bacterial Agents; Anticoagulants; Anxiety; Blood Gas Analysis; Cannula; Citalopram; Counseling; | 2020 |
Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy.
Topics: Animals; Antidepressive Agents; Anxiety; Cell Adhesion Molecules; Citalopram; Corticosterone; Depres | 2021 |
Moderation of the transgenerational transference of antenatal stress-induced anxiety.
Topics: Animals; Anxiety; Citalopram; COVID-19; Crataegus; Disease Models, Animal; Drugs, Chinese Herbal; Fe | 2021 |
Early Developmental Exposure to Fluoxetine and Citalopram Results in Different Neurodevelopmental Outcomes.
Topics: Anxiety; Citalopram; Female; Fluoxetine; Humans; Patch-Clamp Techniques; Pregnancy; Selective Seroto | 2021 |
Anxiety symptom remission is associated with genetic variation of PTPRZ1 among patients with major depressive disorder treated with escitalopram.
Topics: Anxiety; Citalopram; Depressive Disorder, Major; Escitalopram; Genetic Variation; Genome-Wide Associ | 2021 |
Morgellons disease: experiences of an integrated multidisciplinary dermatology team to achieve positive outcomes.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Local; Antipsychotic | 2018 |
Potentiation of morphine-induced antinociception and locomotion by citalopram is accompanied by anxiolytic-like effects.
Topics: Analgesics, Opioid; Animals; Anxiety; Citalopram; Dose-Response Relationship, Drug; Drug Synergism; | 2017 |
Biphasic effects of selective serotonin reuptake inhibitors on anxiety: rapid reversal of escitalopram's anxiogenic effects in the novelty-induced hypophagia test in mice?
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; Behavior, Animal; C | 2018 |
Memantine rescues prenatal citalopram exposure-induced striatal and social abnormalities in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Corpus Striatum; Excitatory | 2018 |
Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzofurans; Citalopram; Depression; Depr | 2018 |
Searching for neural and behavioral parameters that predict anti-aggressive effects of chronic SSRI treatment in rats.
Topics: Aggression; Animals; Animals, Outbred Strains; Anxiety; Brain; Citalopram; Cross-Over Studies; Indiv | 2018 |
Escitalopram-Induced Rash.
Topics: Anxiety; Citalopram; Depression; Drug Eruptions; Exanthema; Female; Humans; Selective Serotonin Reup | 2019 |
Exposure to prenatal antidepressant alters medial prefrontal-striatal synchronization in mice.
Topics: Animals; Antidepressive Agents; Anxiety; Brain; Citalopram; Corpus Striatum; Dendrites; Depression; | 2019 |
Effects of SSRIs on peripheral inflammatory cytokines in patients with Generalized Anxiety Disorder.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; C-Reactive Prot | 2019 |
Commentary on "When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram".
Topics: Alzheimer Disease; Anxiety; Citalopram; Dementia; Humans; Psychomotor Agitation | 2019 |
Upregulation of the dorsal raphe nucleus-prefrontal cortex serotonin system by chronic treatment with escitalopram in hyposerotonergic Wistar-Kyoto rats.
Topics: Animals; Anxiety; Citalopram; Disease Models, Animal; Exploratory Behavior; Feeding Behavior; Food P | 2013 |
Effect of escitalopram on cardiomyopathy-induced anxiety in mice.
Topics: Animals; Anxiety; Cardiomyopathies; Citalopram; Doxorubicin; Heart; L-Lactate Dehydrogenase; Male; M | 2013 |
[Family malediction in the background of panic disorder -- case report].
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Citalopra | 2013 |
Manic episode following deep brain stimulation of the subthalamic nucleus for Parkinson's disease: a case report.
Topics: Antiparkinson Agents; Anxiety; Bipolar Disorder; Citalopram; Deep Brain Stimulation; Electrodes, Imp | 2014 |
Escitalopram or novel herbal mixture treatments during or following exposure to stress reduce anxiety-like behavior through corticosterone and BDNF modifications.
Topics: Animals; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Citalopram; Corticosterone; M | 2014 |
The effects of the estrus cycle and citalopram on anxiety-like behaviors and c-fos expression in rats.
Topics: Animal Communication; Animals; Anxiety; Citalopram; Estrus; Female; Maze Learning; Proto-Oncogene Pr | 2014 |
Behavioural and transcriptional effects of escitalopram in the chronic escape deficit model of depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Body Weight; Chronic Disease; Citalopram | 2014 |
Acute serotonergic treatment changes the relation between anxiety and HPA-axis functioning and periaqueductal gray activation.
Topics: Animals; Anxiety; Buspirone; Citalopram; Corticosterone; Hypothalamo-Hypophyseal System; Male; Motor | 2014 |
Bifidobacteria exert strain-specific effects on stress-related behavior and physiology in BALB/c mice.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Bifidobacterium; Citalopram; Disease Mode | 2014 |
Acute escitalopram but not contextual conditioning exerts a stronger "anxiogenic" effect in rats with high baseline "anxiety" in the acoustic startle paradigm.
Topics: Acoustic Stimulation; Animals; Anxiety; Citalopram; Fear; Male; Rats; Rats, Wistar; Reflex, Startle; | 2015 |
Sex dependent reduction by prenatal stress of the expression of 5HT1A receptors in the prefrontal cortex and CRF type 2 receptors in the raphe nucleus in rats: reversal by citalopram.
Topics: Animals; Anxiety; Citalopram; Corticotropin-Releasing Hormone; Dorsal Raphe Nucleus; Female; GABAerg | 2015 |
Serotonergic, brain volume and attentional correlates of trait anxiety in primates.
Topics: Animals; Anxiety; Attention; Brain; Callithrix; Citalopram; Fear; Female; Heart Rate; Magnetic Reson | 2015 |
The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Cells, Cultured; Citalopram; Diazepam; Disease Models, Animal | 2015 |
Mental health: thinking from the gut.
Topics: Animals; Anxiety; Autistic Disorder; Bacteroides fragilis; Bifidobacterium; Blood-Brain Barrier; Bra | 2015 |
Differences in Anxiety-Like Behavior within a Batch of Wistar Rats Are Associated with Differences in Serotonergic Transmission, Enhanced by Acute SRI Administration, and Abolished By Serotonin Depletion.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Brain; Citalopram; Exploratory Behavior; Fenclonine; Individu | 2015 |
Prenatal stress, regardless of concurrent escitalopram treatment, alters behavior and amygdala gene expression of adolescent female rats.
Topics: Amygdala; Animals; Anxiety; Citalopram; Corticosterone; Disease Models, Animal; Estradiol; Female; g | 2015 |
Cognitive control, reward-related decision making and outcomes of late-life depression treated with an antidepressant.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Anxiety; Citalopram; Cognition; Decision Making; Dep | 2015 |
Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission.
Topics: Animals; Anxiety; Behavior, Animal; Body Weight; Brain; Citalopram; Corticosterone; Depression; Diet | 2015 |
Clinically Useful Genetic Markers of Antidepressant Response: How Do We Get There From Here?
Topics: Antidepressive Agents; Anxiety; Citalopram; Cyclohexanols; Depressive Disorder; Depressive Disorder, | 2015 |
Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress.
Topics: Adrenocorticotropic Hormone; Animals; Anxiety; Behavior, Animal; Body Weight; Brain-Derived Neurotro | 2015 |
High-fat diet-induced metabolic disorders impairs 5-HT function and anxiety-like behavior in mice.
Topics: Animals; Anxiety; Behavior, Animal; Citalopram; Diet, High-Fat; Male; Metabolic Diseases; Mice; Mice | 2016 |
Perinatal citalopram does not prevent the effect of prenatal stress on anxiety, depressive-like behaviour and serotonergic transmission in adult rat offspring.
Topics: Animals; Anxiety; Autoreceptors; Behavior, Animal; Citalopram; Corticotropin-Releasing Hormone; Dise | 2016 |
Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory.
Topics: Animals; Anxiety; Brain; Citalopram; Depression; Disease Models, Animal; Fear; Memory; Rats; Rats, W | 2016 |
May depressed and anxious patients with carcinoid syndrome benefit from treatment with selective serotonin reuptake inhibitors (SSRIs)?: findings from a case report.
Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Anxiety; Carcinoid Heart | 2016 |
Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice.
Topics: Acamprosate; Alcohol Drinking; Animals; Anxiety; Citalopram; Depression; Drug Therapy, Combination; | 2016 |
Positive allosteric modulation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptors differentially modulates the behavioural effects of citalopram in mouse models of antidepressant and anxiolytic action.
Topics: Allosteric Regulation; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Citalopram; Depressi | 2016 |
Therapeutic effects of 10-HzPulsed wave lasers in rat depression model: A comparison between near-infrared and red wavelengths.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Combined Modality Therapy; D | 2016 |
The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Anxiety; Behavior, Animal; Cit | 2016 |
Perinatal exposure to the selective serotonin reuptake inhibitor citalopram alters spatial learning and memory, anxiety, depression, and startle in Sprague-Dawley rats.
Topics: Age Factors; Amphetamines; Animals; Animals, Newborn; Anxiety; Body Weight; Citalopram; Depression; | 2016 |
Recent trends in primary-care antidepressant prescribing to children and young people: an e-cohort study.
Topics: Adolescent; Antidepressive Agents; Anxiety; Child; Citalopram; Cohort Studies; Databases, Factual; D | 2016 |
Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment.
Topics: Animals; Anxiety; Anxiety Disorders; Behavior, Animal; Black or African American; Brain-Derived Neur | 2017 |
Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Depressive D | 2009 |
Effects of acute citalopram on the expression of conditioned freezing in naive versus chronic citalopram-treated rats.
Topics: Animals; Anxiety; Citalopram; Conditioning, Psychological; Disease Models, Animal; Fear; Immobilizat | 2009 |
Possible role of citalopram and desipramine against sleep deprivation-induced anxiety like-behavior alterations and oxidative damage in mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Anxiety; Behavior, Animal; Brain; Citalopram; Desipramine; Ma | 2008 |
Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain-Derived Neuro | 2009 |
Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Anxiety; Citalopram; Depressive Disorder, Major; Female; G | 2009 |
Acute dyskinesia and extrapyramidal disorder in a child after ingestion of escitalopram.
Topics: Acute Disease; Alprazolam; Anti-Anxiety Agents; Anxiety; Basal Ganglia Diseases; Chest Pain; Child; | 2009 |
Acute SSRI-induced anxiogenic and brain metabolic effects are attenuated 6 months after initial MDMA-induced depletion.
Topics: Animals; Anxiety; Axons; Brain; Citalopram; Fluoxetine; Male; N-Methyl-3,4-methylenedioxyamphetamine | 2010 |
Differential effects of acute and repeated citalopram in mouse models of anxiety and depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents, Second-Generation; Anxiety; | 2010 |
Defense style in panic disorder before and after pharmacological treatment.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety; Checklist; Citalopra | 2011 |
Effect of anti-depressants on neuro-behavioural consequences following impact accelerated traumatic brain injury in rats.
Topics: Acceleration; Amitriptyline; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain Injuri | 2010 |
Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Clinical | 2011 |
Changes in regional brain volumes in social anxiety disorder following 12 weeks of treatment with escitalopram.
Topics: Adolescent; Adult; Aged; Anxiety; Anxiety Disorders; Brain; Citalopram; Depressive Disorder; Diagnos | 2010 |
Acute anxiogenic-like effects of selective serotonin reuptake inhibitors are attenuated by the benzodiazepine diazepam in BALB/c mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Citalopram; Corticosterone; Diazepam; Drug | 2011 |
The selective serotonin reuptake inhibitor, escitalopram, enhances inhibition of prepotent responding and spatial reversal learning.
Topics: Animals; Anxiety; Behavior, Animal; Citalopram; Disease Models, Animal; Dose-Response Relationship, | 2012 |
Endogenous ciliary neurotrophic factor modulates anxiety and depressive-like behavior.
Topics: Amitriptyline; Animals; Anxiety; Biogenic Monoamines; Cell Count; Ciliary Neurotrophic Factor; Cital | 2012 |
Treatment of comorbid anxiety and depression with escitalopram: results of a post-marketing surveillance study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Data Interpretation, Sta | 2013 |
Reward responsiveness and fatigue in multiple sclerosis.
Topics: Adult; Anxiety; Attention; Bupropion; Citalopram; Cognition; Depression; Disability Evaluation; Diso | 2013 |
Information processing bias and pharmacotherapy outcome in older adults with generalized anxiety disorder.
Topics: Adult; Aged; Aging; Anxiety; Anxiety Disorders; Attention; Citalopram; Decision Making; Emotions; Fe | 2013 |
Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala.
Topics: Amygdala; Animals; Anxiety; Behavior, Animal; Body Weight; Citalopram; Corticotropin-Releasing Hormo | 2013 |
Successful treatment of patients previously labeled as having "delusions of parasitosis" with antidepressant therapy.
Topics: Antidepressive Agents; Anxiety; Citalopram; Delusions; Depression; Diagnosis, Differential; Female; | 2012 |
Citalopram in children and adolescents with depression or anxiety.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety; Child; Citalopram; Comorbidity; Depre | 2002 |
Differential neurochemical properties of central serotonergic transmission in Roman high- and low-avoidance rats.
Topics: Animals; Anxiety; Autoradiography; Avoidance Learning; Behavior, Animal; Binding, Competitive; Brain | 2003 |
Serotonin transporters are preserved in the neocortex of anxious Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Analysis of Variance; Anxiety; Carrier Proteins | 2003 |
R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety.
Topics: Animals; Anxiety; Citalopram; Conditioning, Psychological; Dose-Response Relationship, Drug; Fear; M | 2003 |
Anxiety sensitivity and modulation of the serotonergic system in patients with PD.
Topics: Adult; Anxiety; Citalopram; Female; Humans; Male; Panic Disorder; Psychometrics; Selective Serotonin | 2004 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; | 2004 |
Alkaloids from Boophane disticha with affinity to the serotonin transporter in rat brain.
Topics: Alkaloids; Animals; Anti-Anxiety Agents; Anxiety; Brain; Citalopram; Medicine, Traditional; Membrane | 2005 |
alpha2-Adrenergic agonists antagonise the anxiolytic-like effect of antidepressants in the four-plate test in mice.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Anti-Anxiety Agents; Antidepressiv | 2005 |
Target brain sites of the anxiolytic effect of citalopram, a selective serotonin reuptake inhibitor.
Topics: Amygdala; Animals; Anti-Anxiety Agents; Anxiety; Citalopram; Conditioning, Psychological; Disease Mo | 2006 |
Prenatal bupropion exposure enhances the cocaine reward and stress susceptibility in adult mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Citalopram; Cocaine; Conditio | 2005 |
Persistent sexual side effects after SSRI discontinuation.
Topics: Adult; Androgens; Anxiety; Bupropion; Cabergoline; Citalopram; Depressive Disorder; Dopamine Agonist | 2006 |
Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety.
Topics: Adrenergic alpha-Antagonists; Alprazolam; Animals; Anxiety; Citalopram; Dose-Response Relationship, | 2006 |
Psychopharmacology of smoking cessation in patients with mental illness.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Arousal; Bupropion; Citalopram; Depression; Depre | 2006 |
Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocam
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antimetabolit | 2007 |
Further evidence supporting a psychological component to irritable bowel syndrome.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Humans; Irritable Bowel Syndrome; Som | 2007 |
Decreased sensitivity to thermal pain in rats bred for high anxiety-related behaviour is attenuated by citalopram or diazepam treatment.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiet | 2007 |
Tickling-induced 50-kHz ultrasonic vocalization is individually stable and predicts behaviour in tests of anxiety and depression in rats.
Topics: Analysis of Variance; Animals; Anxiety; Behavior, Animal; Chromatography, High Pressure Liquid; Cita | 2007 |
Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia.
Topics: Amitriptyline; Analgesics; Anti-Ulcer Agents; Anticoagulants; Antidepressive Agents; Anxiety; Cardio | 2007 |
Consecutive exposure to lamotrigine and citalopram during pregnancy.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Depression; Drug Administration Sched | 2007 |
Rat behavior after chronic variable stress and partial lesioning of 5-HT-ergic neurotransmission: effects of citalopram.
Topics: Analysis of Variance; Animals; Anxiety; Behavior, Animal; Biogenic Monoamines; Brain Injuries; Cital | 2008 |
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
Topics: Adrenal Cortex Hormones; Amphetamine; Animals; Anxiety; Blotting, Western; Body Weight; Central Nerv | 2008 |
Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Brain Mapping; Carbon Isotopes; Case-Contr | 2009 |
Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents.
Topics: Animals; Anxiety; Citalopram; Emotions; Exploratory Behavior; Imipramine; Male; Mice; Motor Activity | 1994 |
Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
Topics: 1-Naphthylamine; Aggression; Animals; Anxiety; Binding, Competitive; Citalopram; Depression; Fluoxet | 1997 |
Central serotonergic systems in the spontaneously hypertensive and Lewis rat strains that differ in the elevated plus-maze test of anxiety.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Behavior, Animal; Citalopram; Female; Hipp | 1997 |
The effect of drugs acting on CCK receptors and rat free exploration in the exploration box.
Topics: Adrenergic Uptake Inhibitors; Animals; Anxiety; Benzodiazepinones; Citalopram; Desipramine; Devazepi | 1997 |
Acute and chronic citalopram treatment differently modulates rat exploratory behavior in the exploration box test: no evidence for increased anxiety or changes in the [3H]raclopride binding.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Anxiety; Citalopram; Desipramine; Dopam | 1999 |
Effects of conditioned fear stress on serotonin neurotransmission and freezing behavior in rats.
Topics: Animals; Anxiety; Behavior, Animal; Citalopram; Conditioning, Psychological; Fear; Male; Microdialys | 1999 |
The effect of citalopram treatment on platelet serotonin function in panic disorders.
Topics: Adult; Anxiety; Blood Platelets; Citalopram; Depression; Female; Humans; Male; Middle Aged; Panic Di | 2000 |
[Behavioral and neurochemical study on the mechanism of the anxiolytic effect of a selective serotonin reuptake inhibitor, a selective serotonin1A agonist and lithium carbonate].
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Brain Chemistry; Cital | 2001 |
Brief report: citalopram in child and adolescent depression with anxiety.
Topics: Adolescent; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Child; Citalopra | 2001 |
Role of 5-HT1A receptors in the mediation of acute citalopram effects: a 8-OH-DPAT challenge study.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Brain; Citalopram; Drug Synergism; Explora | 2002 |
Interactions of 5HT reuptake inhibitors and ethanol in tests of exploration and anxiety.
Topics: Animals; Anxiety; Citalopram; Desipramine; Drug Interactions; Ethanol; Exploratory Behavior; Fluoxet | 1988 |
Behavioral interactions of fluoxetine and other 5-hydroxytryptamine uptake inhibitors with ethanol in tests of anxiety, locomotion and exploration.
Topics: Animals; Anxiety; Citalopram; Desipramine; Ethanol; Exploratory Behavior; Fluoxetine; Fluvoxamine; M | 1988 |